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 Prodrug discovery and development in the pharmaceutical industry 
have been hampered by a lack of knowledge on activation pathways. Such 
knowledge would de-risk prodrug campaigns by enabling proper selection of 
preclinical animal models, prediction of pharmacogenomic variability, 
and identification of drug-drug interactions. Technologies for annotation of 
activating enzymes have not kept pace with the growing need for it. Activity-based 
protein profiling (ABPP) has matured considerably in recent decades, leading to 
widespread use in drug discovery. Here, we report the extension of competitive 
ABPP to prodrug-activating enzyme (PAE) identification in SILAC cell 
lysates using a modified fluorophosphonate (FP) probe and MS-based 
identification. This was followed by characterization of the new PAE in vitro, as well 
as in mouse tissue lysates and by single-pass intestinal perfusions (SPIP). 
Focusing on the ester prodrug valacyclovir (VACV), we modified the FP 
probe using an aminomethylbenzyl phosphonate ester structurally based on the 
serine protease inhibitor 4-(2-aminoethyl)benzenesulfonyl fluoride, which 
extinguishes VACV activation in Caco-2 cells, our proteome of interest, and inhibits 
BPHL, the only confirmed VACV PAE to date. The novel probe, AMB-FP, identified 
serine hydrolase RBBP9 as another activating enzyme in Caco-2 cells, which was 




emetine abolished VACV activation in Caco-2 lysates, suggesting that RBBP9, not 
BPHL, is the major presystemic VACV-activating enzyme.  
Kinetic characterization of RBBP9 revealed a single-binding stoichiometry 
and a catalytic efficiency comparable to that of BPHL (kcat∙KM-1 = 104 mM-1∙s-1). 
Emetine inhibition data from VACV hydrolysis assays in jejunum and liver soluble 
lysates of wildtype (WT) and Bphl-knockout (KO) mice revealed that RBBP9 and 
BPHL are co-equal mediators of VACV activation in the liver, but that RBBP9 is 
the predominant PAE in the jejunum. Furthermore, the data indicated that these 
two enzymes are likely the only major enzymes involved in VACV activation in 
these tissues. Finally, SPIP data from WT mice with and without emetine pre-
perfusion confirmed the RBBP9-dependence of VACV presystemic activation as 
portal vein samples showed >50% increase in unactivated VACV in emetine-
treated mice. Importantly, this was the first evidence of RBBP9 VACV activation in 
a more physiologically relevant system than lysates. Based on these results, we 
envision that others might use the cABPP approach in the future for global, rapid, 
and efficient discovery of prodrug-activating enzymes in situations where 







 Today’s lead compounds that emerge from medicinal chemistry and drug 
discovery efforts are often not optimizable for pharmacokinetic and 
pharmacodynamic performance, leading to deficiencies in one or more of these 
attributes as a result of this tradeoff. Many of the resulting new chemical entities 
(NCEs) with these deficiencies are halted during preclinical trials, but some survive 
to become investigational new drugs (INDs) and enter costly human clinical trials 
with a high risk of failure. Clinical-stage failures can translate to massive financial 





Figure 1.1. Schematic illustration of the prodrug strategy.1 
Reproduced with permission from ref. 1.  
Formulation approaches are typically attempted first but are best suited for 
issues of gastrointestinal stability or discomfort,2 poor solubility,3 poor organoleptic 
properties,4 or excessive absorption rate.5 When reformulation fails or is deemed 
inadvisable, a common alternative is a chemical approach known as the prodrug 
strategy, in which the IND is derivatized to an inactive form (“prodrug”) devoid of 
the limiting deficiencies seen in the original (“parent”) drug. At the appropriate time 
following administration, the prodrug reverts chemically and/or enzymatically to the 
parent drug (Figure 1.1). Though the reliance on prodrugs as a late-stage salvage 
strategy is still the norm, early-stage implementation is being recognized as a 
prudent way to avoid repeating expensive in vivo studies already carried out with 




feasible and cost-effective as a result of post-genomic era advances in technology 
and knowledge.6  
From a U.S. regulatory perspective, prodrugs can be brought to market 
faster and at less cost since their New Drug Applications (NDAs) are fileable under 
section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act, wherein the 
application “contains full reports of safety and effectiveness but where at least 
some of the information required for approval comes from studies not conducted 
by or for the applicant and for which the applicant has not obtained a right of 
reference.”7 Essentially, this permits the filing of prodrugs using some or all of the 
data provided in the filing of the active drug even if the applicant does not have the 
right to reference that data, thereby shortening the path to approval. Filed this way, 
prodrugs extend the patent exclusivity period of a previously approved drug by five 
years if the prodrug is not an ester, salt, or hydrate of an existing NCE, or otherwise 
by three years if one or more non-bioavailability/bioequivalence studies were 
required for approval and completed by the applicant. In some cases, this patent 
life extension can single-handedly justify the development of a prodrug. 
The prodrug strategy has yielded blockbuster drugs spanning numerous 
drug classes, including antivirals (e.g. valacyclovir), antihyperlipidemics (e.g. 
simvastatin), and antihypertensives (e.g. enalapril), with 15% of the top selling 
drugs on the market in 2009 categorized as prodrugs.8 Recent estimates place the 
prevalence of prodrugs worldwide at 10–14% of all approved drugs,9 illustrating 




Enzymatic Activation Pathways 
A prodrug must be activated, i.e. reverted to the parent drug, in vivo prior to 
exerting its pharmacological effect(s). Thus, the site and rate of activation for a 
given prodrug can be strongly predictive of its clinical success. Recognizing the 
importance of prodrug activation, a 2009 publication by Dr. Kuei-Meng Wu at the 
U.S. Food and Drug Administration’s Center for Drug Evaluation and Research 
(CDER) proposed a prodrug classification system with two main categories based 
on the site of activation: intracellularly and extracellularly activated agents are 
respectively designated Type I and Type II, each with further subdivisions (IA/IB 
and IIA/IIB/IIC) based on the specific tissue(s) or compartment(s) of activation.10 
While these classifications are only a framework, they emphasize the importance 
of considering activation to aid regulatory review and risk assessment of prodrugs. 
In order to realize its full utility, a prodrug should only be activated once it 
has cleared all impediments to the parent drug’s performance, as a parent drug 
liberated too soon or too rapidly from its prodrug may not be able to reach the site 
of action in sufficient quantity. Conversely, a parent drug that is liberated too late 
or too slowly may result in clearance of the prodrug before the drug can reach 
therapeutic levels at the site of action. Though a small percentage of prodrugs are 
thought to be activated chemically, i.e. spontaneously, most prodrugs rely on 
enzymatic catalysis for activation. Hence, identifying prodrug-activating enzymes 
(PAEs) is vital for the same reasons identifying drug-metabolizing enzymes is: it 
enables the discovery and prediction of (1) prodrug interactions with other drugs,11 




and safety; (2) interspecies differences in enzyme specificity, kinetics, and tissue 
distribution of PAEs that can better inform the selection of preclinical animal 
models; (3) pharmacogenomic variants that can predispose individuals to low 
efficacy or high toxicity when taking an average dose of a prodrug; and (4) new 
targeted prodrugs, structurally designed to be activated by a specific enzyme or 
set of enzymes. 
New Chemoproteomic Methods for Identification of PAEs 
Exploratory studies for PAE identification in vitro are identical to those used 
in reaction phenotyping, the identification of drug-metabolizing enzymes (DMEs) 
and the quantitation of their relative contributions to the metabolized fraction, fm, of 
a drug.13,14 This involves the incubation of the prodrug with enzymes and inhibitors 
of interest, whose selection will depend on qualitative data or intuition about the 
expected routes and sites of biotransformation. Total hepatic lysate, produced by 
homogenization then sedimentation of cell debris at 9,000 g to yield the “S9” 
fraction, and/or microsomes and plasma are tested for most prodrugs, with 
intestinal S9 and/or microsomes also investigated in the case of oral prodrugs 
specifically. Pre-incubation with cofactors like nicotinamide adenine dinucleotide 
(NADH) or divalent metal cations/chelators and nonselective mechanism-based 
inhibitors (MBIs) like bis(4-nitrophenyl)phosphate (BNPP) or 1-aminobenzotriazole 
(ABT) helps to broadly identify classes of enzymes involved in the activation 
process. Once a class of PAE is identified, well-characterized specific inhibitors or 
antibodies and recombinantly overexpressed enzymes are used to confirm the 




methods are that the PAE must be characterized enough to be a candidate DME 
and must either be compatible with heterologous expression systems or have 
commercially available selective inhibitors or antibodies. If these conditions are not 
met, a more laborious approach is utilized: activity-guided fractionation. Here, the 
PAEs are purified from lysate by several rounds of fractionation, using prodrug 
activation assays as a readout and fold purification and in-gel visualization as an 
endpoint. After the active fractions are sufficiently purified, PAEs are 
unambiguously identified by N-terminal sequencing or, more recently, bottom-up 
mass spectrometry.15 While this approach is well-established and tested, each 
round of purification and the ensuing assays is time-consuming, leaving much 
room for improvement. 
 
Figure 1.2. Schematic diagram of the central conceit and workflow of ABPP.16 
(A) General ABPP scheme with both gel- and MS-based readout. Probes label enzyme subsets in 
complex proteomes, enabling visualization or purification and identification. RG, reactive group; 
BG, binding group; TAG, reporter group (e.g. rhodamine or biotin). (B) Competitive ABPP scheme 







Since the turn of the century, a new streamlined approach for profiling 
protein activity in complex proteomes termed activity-based protein profiling 
(ABPP) has been pioneered and popularized by Dr. Benjamin Cravatt and 
colleagues.17–19 The fundamental feature of ABPP is the chemical probes, bearing 
an MBI for active-site interrogation at one end and a reporter functionality, e.g. a 
fluorophore or affinity tag, at the other end for downstream enrichment and 
detection in gel or by mass spectrometry (MS). The MBI moiety covalently binds a 
nucleophilic catalytic residue, in effect, labeling the enzyme in proportion to its 
activity. Anything that affects a labeled enzyme’s activity, and therefore its signal 
intensity, can be detected, such as active site occupants, e.g. substrates and 
competitive inhibitors, making this technique extremely promising for PAE 
identification and drug discovery (Figure 1.2).20–22 Theoretically, one probe-
prodrug competitive ABPP (cABPP) experiment with MS-based proteomic 
identification can identify all relevant PAEs for a prodrug in an enzyme preparation 
if they are all susceptible to the MBI. It follows that probes with wide reactivity 
profiles are ideal for this application as they can assay the active site occupancy 
of several enzymes in parallel, increasing throughput. Previously, our lab 
demonstrated proof of concept by confirming activation of ester prodrug oseltamivir 
by carboxylesterase 1 (CES1) in competitive labeling experiments with the pan-
serine hydrolase MBI fluorophosphonate-polyethylene glycol-biotin (FP-PEG-




The Need for Study of Ester PAEs 
One of the primary factors contributing to prodrug activation kinetics is the 
type of chemical reaction required for activation. By far, the most common type is 
hydrolysis, with carboxylic acid esters encountered most. This functional group 
offers synthetic simplicity and strikes a fine balance between chemical stability and 
enzymatic susceptibility. Additionally, numerous drugs contain phenoxyl, carboxyl, 
and hydroxyl groups, making ester prodrugs highly accessible. The versatility of 
ester prodrugs is reflected in the structural diversity of promoieties that can be 
utilized, often increasing bioavailability via solubility and/or permeability depending 
on their physicochemical and stereoelectronic properties. For more than half a 
century, ester xenobiotics have been known to be metabolized by efficient and 
often broad-spectrum hydrolases enriched in the epithelia of drug-metabolizing 
organs as well as the bloodstream.24 This made esters a very safe choice for 
prodrug derivatization, especially before the proliferation of genomic and structural 
data made target-based design possible. The effective guarantee of first-pass 
ester hydrolysis is a primary reason for the prevalence of esters in the prodrug 
space, especially for oral administration. 
Despite the ubiquity of esters in prodrugs and drugs, mammalian and 
human esterases involved in xenobiotic metabolism remain poorly characterized, 
with the main exceptions being the carboxylesterase isoforms CES1 and CES2. 
Tissue-enriched respectively in the liver and small intestine, CES1 and CES2 
hydrolyze a broad variety of esters, protectively converting xenobiotics to more 




hydrolases (SHs) cleave amides, carbamates, and thioesters, and are important 
DMEs and PAEs of several bioactive agents25,26 and prodrugs.27–30 In nearly all 
instances CESs were reported to be PAEs, the publications came several years 
after prodrug approval, attesting to the sluggish state of PAE annotation in spite of 
the growing awareness of clinically significant CES genovariants. 
Valacyclovir and Valacyclovirase 
 
Scheme 1.1. Hydrolysis of valacyclovir to acyclovir and L-valine. 
Outside the CES family, a few unique ester PAEs have been discovered—
our lab identified a fascinating SH responsible for activation of the antiviral prodrug 
valacyclovir (VACV, Scheme 1.1), biphenyl hydrolase-like protein (BPHL).31 
VACV, the L-valyl ester of nucleoside mimetic acyclovir (ACV), itself a prodrug, 
was developed in the early 1990s,32 10 years before the discovery of BPHL. VACV 
had an oral bioavailability three to five times that of ACV but, peculiarly, had a 
slightly lower log P due to the α-amino group in valine, making increased passive 
permeability unlikely. This mystery was solved when VACV was shown to be the 
first non-peptidic substrate for intestinal oligopeptide transporter PepT1, an 
apically expressed, proton-dependent transporter of di- and tripeptides.33,34 After 
PepT1-mediated uptake into enterocytes, VACV is thought to undergo first-pass 
hydrolysis by BPHL in both the gut and liver. BPHL is unique among SHs for its 
stringent specificity for primary α-amino acid esters of primary and secondary 




prodrugs seeking increased absorption via uptake by PepT1 and presystemic 
activation by BPHL, termed the double-targeted prodrug strategy (Figure 1.3).39,40 
 
Figure 1.3. Schematic model of the double-targeted prodrug strategy.35 
A schematized mechanism for the increased oral absorption of PEPT1- and BPHL-targeting 
(double-targeted) amino acid-ester prodrugs. D, drug; aa, amino acid; VACVase, BPHL. 
Reproduced with permission from ref. 35. 
Though BPHL was considered to have the highest fm for VACV, there was 
considerable evidence of additional VACVases in the gut wall. After 
immunoprecipitation of BPHL from Caco-2 cell lysate, the cell line in which it was 
first identified as a VACVase, there was significant residual activity remaining.41 
Furthermore, Bphl-knockout (KO) mice showed no significant differences in PK 
parameters of VACV or ACV compared to wildtype (WT) after single-dose oral and 
IV studies.42 Clearly, BPHL is not obligatory for presystemic or systemic activation 
of VACV, begging the question of what other PAEs could be involved. 
Specific Aims 
For this dissertation project, the original goal was to use cABPP to identify 
the undiscovered VACVase(s) in Caco-2 cells. Given the near-total inhibition of 




commercially available FP activity-based probes (ABPs) to investigate. These 
probes did not inhibit Caco-2 VACVase activity, however, meaning that our first 
aim would be to synthesize a novel anti-VACVase FP ABP, validate its inhibitory 
activity, and visualize its unique targets. The second aim was to develop and 
optimize an MS-based cABPP protocol with the novel FP to identify the 
VACVase(s) in Caco-2 lysate. The final aim was to validate and characterize the 
discovered VACVase(s) in vitro and in situ to understand the clinical relevance of 
the findings. 
Succeeding in these aims would represent the first documented application 
of ABPP to the MS-based determination of an unidentified PAE, paving the way 
for more widespread adoption in both industry and academia as a prodrug 
discovery and development tool. Given the relative maturation of ABPP as a field 
and numerous enzyme classes now boasting class-selective ABPs, we envision 
that this approach can take hold sooner rather than later in pharmaceutical R&D. 
Ultimately, a stronger knowledge of physiological factors affecting prodrug 
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Synthesis and Validation of Novel Fluorophosphonate Probes Targeting 
VACV PAEs 
Introduction
 The serine hydrolase (SH) enzyme superfamily, which includes BPHL and 
roughly one percent of the human proteome, is exceptionally large for an enzyme 
class. Though they are diverse in function, SHs are named for their common 
conserved feature: a catalytic Ser nucleophile that attacks the carbonyl electrophile 
of its typical substrates. The enhanced nucleophilicity of Ser distinguishes it from 
all other Ser sidechains in proteins and makes the subclass ideal for probing by 
activity-based protein profiling (ABPP), especially fluorophosphonate (FP) activity-
based probes (ABPs).18,43 Structurally inspired by toxic organophosphorus nerve 
agents like sarin and diisopropyl fluorophosphate, FPs combine phosphonate 
transition state analogs of carboxylic acid ester substrates with the well-tuned 
electrophilicity of the fluoride leaving group for selective inactivation of the catalytic 
Ser nucleophile, thus irreversibly inhibiting SHs by forming a highly stable 
phosphonylated adduct via addition-elimination. As countless studies over the 
years have demonstrated, FP ABPs are remarkably selective for SHs at working 
concentrations, not binding appreciably to noncatalytic Ser residues or other 




however, FP ABPs are much less discerning since they lack structural features 
necessary to bias their reactivity towards a smaller set of SHs.  
 
Scheme 2.1. Structures of AEBSF and probe modifications. 
(A) Structure of AEBSF and its alcohol analog, tyramine. (B) Tyramine was not amenable to 
phosphonate esterification (top), leading to the use of the more nucleophilic isobaric isomer 4-
(aminomethyl)benzyl alcohol. 
While class-wide probe promiscuity is generally useful, with estimates of SH 
coverage by FP-biotin in mouse tissue lysates at 80–85%,44 hBPHL, the only 
known valacyclovir (VACV) PAE prior to this work, is among the 15–20% not 
labeled by FP ABPs under typical conditions. To generate a useful probe of 
VACVases, we sought to replace the ethyl group in the commercially available FP 
with a moiety that would lead to inhibition of BPHL. Pan-serine protease inhibitor 
4-(2-aminoethyl)benzenesulfonyl fluoride (AEBSF, Scheme 2.1) which 
sulfonylates the active Ser in BPHL and has been crystallographically 
characterized in this complex,45 was chosen as this moiety because it also 
extinguishes all VACVase activity in Caco-2 lysate (Figure 2.1). The amino group 





could be harnessed in an FP ABP to label BPHL and other hypothetical VACV 
PAEs with localized anionic regions within their active sites. 
 
 
Scheme 2.2. Probe structures. 
Structures of FP-PEG-biotin (top), FP-TAMRA, AMB-FP-TAMRA, and AMB-FP-alkyne (bottom). 
Esterification of the phosphonate group with tyramine, the alcohol analog of 
AEBSF, into the basic FP probe structure was ultimately infeasible due to the 
phenol’s lack of nucleophilicity. An isobaric alcohol with more nucleophilicity, 4-
(aminomethyl)benzyl alcohol (AMB), in which a methylene group adjacent to the 




was used instead to preserve the size of the moiety. Thus was generated a novel 
aminomethylbenzyl-FP (AMB-FP, Scheme 2.2), which, to our knowledge, is the 
first reported FP ABP with a primary amino group, and one of only a handful in 
which the ethyl substituent has been replaced by a specificity group. Two different 
probes were synthesized: one with a carboxytetramethylrhodamine group (AMB-
FP-TAMRA) and one with a terminal alkyne (AMB-FP-alkyne) for “click chemistry” 
cycloaddition with an azide-functionalized biotin group. A directly biotinylated 
version of the probe was synthesized in small quantities but was too unstable for 
use. 
The new AMB-FP inhibited VACV activation in Caco-2 lysate but did not 
inhibit rBPHL, suggesting that it was inhibiting one or more undiscovered VACV 
PAEs. Moreover, the novel probe inhibited VACV activation in Bphl-knockout (KO) 
mouse tissue lysates. In both these experiments, the commercial FP probe did not 
inhibit VACV activation. In-gel comparison of labeling profiles in various lysates 
demonstrated a large, shared target set with a minority of targets unique to each 
probe. Here we report the synthesis and validation of AMB-FP-TAMRA and AMB-








Scheme 2.3. Synthetic route from starting material to intermediate 5. 
 The synthetic routes to alkynylated probe 15 and fluorogenic probe 10, 
outlined in Scheme 2.3, Scheme 2.4, and Scheme 2.5, were ten-step, linear 
syntheses with an overall yield of 2.2% and 0.8%, respectively. Starting with 1,10-
decanediol, monoiodination in hot hydriodic acid gave 1 in 61% yield after 
purification. Protection of the remaining alcohol by a trityl group was accomplished 
with trityl chloride and N,N-diisopropylethylamine in dichloromethane, yielding 
iodoether 2 in 88% yield following purification. The phosphonate group was 
appended by a standard Arbuzov reaction in triethyl phosphite, generating diethyl 
phosphonate 3 in 56% yield. Hydrochloric acid in tetrahydrofuran (THF) was used 
to deprotect the trityl ether and provide 4 in 99% yield after purification, which was 
then activated to carbonate ester 5 by disuccinimidyl carbonate in acetonitrile in 





Scheme 2.4. Synthetic route from intermediate 5 to AMB-FP-TAMRA (8).  
Only the 5-TAMRA isomer is shown, but an equimolar mixture of 5- and 6-TAMRA isomers was 
synthesized. 
At this point, the syntheses diverge in the order of steps due to the cost of 
the TAMRA 5-amino-1-pentanamide reagent and its lability towards the 
fluorinating agent used to generate the fluorophosphonate. Specifically, the free 
carboxylate group on the phenyl ring can be converted to an electrophilic acyl 
fluoride in the presence of diethylaminosulfur trifluoride.46 Thus, the route to 
TAMRA probe 8 required that the fluorophosphonate be generated prior to addition 
of the TAMRA moiety. The free phosphonic acid was generated by dealkylation of 
5 via bromotrimethylsilane in dichloromethane and was carried forward without 
purification. Monoesterification to intermediate 6 was performed directly afterwards 
via a procedure adapted from Burger and Anderson,47 in which 
dicyclohexylcarbodiimide (DCC) is used as a coupling agent in refluxing THF. DCC 
in THF was added to the reaction mixture dropwise over 2 h, providing 7 in 17% 
yield over two steps after purification by preparative LC. Next came installment of 
the fluorine-phosphorus bond by treatment with diethylaminosulfur trifluoride at 




was appended in DMSO, replacing the succinimidyl group to generate the 
penultimate carbamate 7 after preparative LC purification in 34% yield over 2 
steps. Removal of the Boc group with TFA in DCM gave the final TAMRA probe 8 
in 70% yield (0.8% overall yield over ten steps) with purity determined by HPLC to 
be >95%. 
 
Scheme 2.5. Synthetic route from intermediate 5 to AMB-FP-alkyne (11). 
 The synthesis of alkynylated probe 11 from 5 begins with addition of 1-
amino-3-butyne to the carbonate in acetonitrile to generate alkynylcarbamate 9 
with a yield of 87% after flash chromatography. This was followed by the same 
steps used to synthesize probe 8, generating compounds 10 and 11 by successive 
phosphonate dealkylation and monoesterification (19% over two steps), 
fluorination and Boc deprotection (73% over two steps). Compound 11 was 
synthesized with an overall yield of 2.2% over ten steps and >95% purity as 




VACV Activation Probe Inhibition Assay 
 
Figure 2.1. Inhibition of VACV activation in Caco-2 S100 and rBPHL. 
Activation of VACV in Caco-2 S100 and rBPHL with the listed inhibitors. Both FP probes were 
incubated at 20 μM. AEBSF (500 μM) served as positive control. Results are shown as mean ± SD 
(n = 3). ***p < .001 compared to DMSO control by unpaired t-test. 
 In Caco-2 cytosol at pH 7.4, AMB-FP-alkyne at 20 μM inhibited VACV 
hydrolysis to 55% of DMSO control (Figure 2.1). In contrast, 20 μM each of FP-
PEG-biotin and FP-TAMRA did not appreciably inhibit VACV hydrolysis, even with 
incubation times up to an hour. With purified rBPHL, no inhibition was observed 
with any probe up to 20 μM. Finally, in Bphl-KO mouse jejunum and liver lysates, 
VACV activation was reduced to 66% and 71% of DMSO control, respectively, 
after incubation with 20 μM AMB-FP-alkyne (Figure 2.2). Taken together, these 
data suggest that AMB-FP-alkyne is inhibiting one or more unidentified VACV 





Figure 2.2. Inhibition of VACV activation in Bphl-KO mouse tissue S100. 
Inhibition of VACV activation in both jejunum and liver S100 fractions by AMB-FP-alkyne (20 μM) 
shows roughly similar results in both tissues. **p < .01 and ***p < .001 compared to DMSO control 
by unpaired t-test. 
Optimization of In-Gel Probe Labeling Conditions 
 With 0.5 μM AMB-FP-TAMRA, the most abundant Caco-2 cytosolic proteins 
were detectably labeled (Figure 2.3). Many more targets were visibly labeled at 5 
μM, as expected, though two or three bands showed a constant signal at all 
concentrations and timepoints (e.g. thin closed arrow), implying that with the 
stoichiometries employed at the 0.5 μM probe concentration, the labeling reaction 
proceeded to completion. Another set of bands showed a time-dependent, 
concentration-independent labeling profile, with constant labeling across probe 
concentrations but greater labeling at later timepoints (e.g. thick filled arrow). The 
labeling of these enzymes was rate-limited by insufficient binding affinity and/or 
reactivity specific to the enzyme-probe pair. Conversely, other enzymes showed a 
concentration-dependent, time-independent labeling profile, with constant labeling 








































open arrow). Such enzymes react quickly with the probe such that labeling has 
plateaued at 2 min, likely meaning that the reaction is rate-limited by probe 
concentration. Finally, some enzymes show both time and concentration 
dependence (e.g. thick hollow arrow). At 5 μM, two bands show the highest 
intensities by a wide margin: one right below the 65 kDa marker, possibly CES1, 
and one just above the 23 kDa marker, possibly lysophospholipase A2 (LYPA2). 
 
Figure 2.3. Time and concentration optimization of gel-based ABPP. 
Optimization of labeling time and AMB-FP-TAMRA concentration for gel-based ABPP studies. 





In-Gel Probe Target Comparison in Caco-2 
 
Figure 2.4. Comparison of probe targets in Caco-2 S100. 
Targets of AMB-FP-TAMRA (VFP1-Rh, ) and FP-TAMRA (FP-Rh) in Caco-2 S100. Lanes 1 and 6 
served as negative controls. Lanes 3 and 4 show targets unique to each probe. VFP1-B = AMB-
FP-biotin; FP-B = FP-biotin. 
 The baseline labeling profiles of equimolar AMB-FP-TAMRA and FP-
TAMRA are seen in lanes 2 and 5 (Figure 2.4). To visualize unique targets, these 
same reactions were also carried out with pre-treatment by the opposing probe 
(i.e. FP-PEG-biotin pre-treatment prior to labeling with AMB-FP-TAMRA and vice 
versa). These results are seen in lane 3 (AMB-FP-TAMRA) and lane 4 (FP-
TAMRA), with a greater number of bands and higher band intensities seen with 
FP-TAMRA. Lanes 1 and 6 are control reactions with pre-treatment by the same 




their fluorogenic counterparts. While AMB-FP-alkyne suitably blocked all AMB-FP-
TAMRA labeling (lane 1), FP-PEG-biotin was not as effective in this regard. 
However, this may be due to the fact that the reporter group, contrary to intuition, 
can have a significant impact on probe reactivity profiles. 
In-Gel Probe Target Comparison in Cell/Tissue Lysates 
 
Figure 2.5. Comparison of probe targets in a panel of cell/tissue lysates. 
Fluorescent gel scan of labeling of cell and tissue lysates to completion (30 min) with FP-TAMRA 
(5 μM) or AMB-FP-TAMRA (10 μM). Unique targets are boxed in red for FP-TAMRA or blue for 
AMB-FP-TAMRA. 
To visualize the differences in labeling profiles in other proteomes, AMB-
FP-TAMRA and FP-TAMRA were screened against a panel of cell and tissue 
lysates. AMB-FP-TAMRA was tested at twice the concentration used for FP-
TAMRA (10 vs. 5 μM) to compensate for its slower labeling kinetics, likely due to 
increased steric bulk near the reactive center. The visible bands demonstrate that 




unique bands, boxed in red, than does AMB-FP-TAMRA, which might be due to 
its smaller size, enabling access to more restrictive active sites. AMB-FP-TAMRA 
also labels unique targets, boxed in blue, though generally, the activity of these 






 As a tool in chemical biology, ABPs are highly versatile due to their 
structural modulability. FPs provide an ideal scaffold for diversification since the 
phosphonate group, compared to carbonyl (or other sp2 carbon-based) 
electrophiles, has an extra substituent. In most FPs, including the original FP18,43, 
this is an ethyl substituent as a result of synthetic convenience from the use of 
cheap and readily available triethyl phosphite to install the phosphonate group. To 
synthesize a novel AMB-FP probe with a 4-(aminomethyl)benzyl (AMB) ester in 
place of the ethyl group, we used a mostly conventional synthetic route adapted 
from the synthesis of FP-PEG-biotin by Xu et al.48 Differences include (1) the initial 
use of hydriodic acid to monoiodinate the starting diol directly without protection, 
(2) the use of an acid-labile trityl protecting group on the iodoalcohol in place of the 
benzyl group, (3) the double dealkylation of the diethyl phosphonate by 
bromotrimethylsilane in lieu of monodealkylation by lithium azide, and (4) the 
obligatory inclusion of a phosphonate esterification step to install the AMB moiety.  
The chemical transformation of one hydroxyl group on a symmetric diol is 
difficult to achieve selectively due to the chemical equivalence of the 
functionalities. Attempts to selectively protect one of the two alcohols in high yield 
were not fruitful. Failures notwithstanding, iodination in excess hot hydriodic acid 
was surprisingly selective over the timescales and stoichiometries employed, 
resulting in much less of the diiodide byproduct than would be expected purely 
entropically. The second adjustment, the use of an acid-labile trityl protecting 




and ease of deprotection. Hydrogenolysis, the preferred method of benzyl ether 
deprotection, carries significant risks of explosion and fire normally seen with 
pressurized hydrogen gas. In contrast, trityl ethers are cleanly and efficiently 
reverted to the alcohol in mild acid. The third change was the double dealkylation 
of the phosphonate using the well-known method of silylation and solvolysis 
pioneered by McKenna et al.49 using bromotrimethylsilane followed by an aqueous  
solvent mixture. Finally, dicyclohexylcarbodiimide was used as a coupling agent 
for selective but low-yielding phosphonate monoesterification in a method first 
reported by Burger and Anderson.47 
The modification of the commercial FP probe to the novel AMB-FP probe 
resulted in the inhibition of unannotated VACVase activity in Caco-2 cell lysate, as 
inferred from its simultaneous lack of rBPHL inhibition. We corroborated this 
conclusion by observing the same inhibition of VACV activation in Bphl-KO mouse 
jejunum and liver lysates, which are definitively devoid of Bphl. When figuring out 
the proper labeling conditions in Caco-2 S100 with the new probe, it was observed 
that Caco-2 S100 contained a proteome of diverse abundances and reactivities, 
featuring enzymes possessing any and all combinations of time- and probe 
concentration-dependent labeling profiles. Comparison of AMB-FP-TAMRA and 
FP-TAMRA labeling demonstrated that the commercial probe is more promiscuous 
and has faster kinetics, but AMB-FP-TAMRA has a few unique targets in both 
Caco-2 S100 and other lysates. The slower labeling kinetics, likely due in part to 
the bulky AMB group near the reactive electrophile, may be beneficial for observing 




design for the synthesis of broad-spectrum probes with complementary reactivities 







Synthetic Materials and Equipment 
All reagents were commercially available and used without further 
purification. 1H and 13C NMR spectra were obtained on Varian 400 or 500 MHz 
spectrometers and 31P and 19F spectra were obtained on a Varian 500 MHz 
spectrometer at the indicated frequencies in the indicated deuterated solvents. 
Chemical shifts are reported as δ (ppm) relative to either the residual solvent peak 
set to a reference value or to the tetramethylsilane internal standard peak set to 
0.0 ppm. Mass spectrometric analysis was performed using an Agilent 6230 TOF 
HPLC-MS. Flash column chromatography was carried out on 240 mesh silica gel 
(Sigma-Aldrich). Preparative LC was performed on the Shimadzu LC-8A model 
with SCL-10A VP system controller, SPD-M20A Prominence diode array detector, 
FRC-10A fraction collector, and a 5-valve manual injection port equipped with a 10 
mL sample loop. Thin-layer chromatography (TLC) was performed on 0.2 mm 
thickness silica gel plates with fluorescent indicator (Sigma-Aldrich). Developed 
TLC plates were visualized by UV illumination at 254 nm, phosphomolybdic acid 
staining, dimethylaminocinnamaldehyde staining, p-anisaldehyde staining, or 
iodine staining. 
10-Iodo-1-decanol (1) 
A solution of 1,10-decanediol (3 g) in toluene (40 mL) was heated to 90oC and to 
it was added 57% HI solution (8 mL). The mixture was stirred at this temperature 




bubbling was observed. Saturated Na2S2O3 solution was then added (2 mL) and 
allowed to stir until the toluene phase was fully decolorized. After separating the 
organic and aqueous layers, the aqueous layer was extracted with Et2O (3 x 20 
mL). Organic fractions were combined and washed with brine and dried over 
Na2SO4. The crude product was concentrated in vacuo and chromatographed on 
silica gel (5-50% EtOAc:hexanes) to give 3.01 g of a colorless oil (yield = 61%): 1H 
NMR (400 MHz, CDCl3) δ 3.63 (t, J = 6 Hz, 2H), 3.18 (t, J = 8 Hz, 2H), 1.81 (quint, 
J = 8 Hz, 2H), 1.56 (quint, J = 7 Hz, 2H), 1.29–1.43 (br, 13H); 13C NMR (100 MHz, 
CDCl3) δ 63.0, 33.5, 32.8, 30.5, 29.5, 29.4, 29.3, 28.5, 25.7, 7.4. 
10-Triphenylmethoxy-1-iododecane (2) 
To a solution of 1 (5.7 g) and N,N-diisopropylethylamine (DIEA, 3.8 mL) in DCM 
(80 mL) was added Ph3CCl (6.9 g) and 4-dimethylaminopyridine (50 mg), which 
were stirred together at RT for two days. The solvent was removed in vacuo and 
the residue was chromatographed on silica gel (100% hexanes-3% 
EtOAc:hexanes) to give 9.33 g of pale yellow oil (yield = 88%): 1H NMR (500 MHz, 
CDCl3) δ 7.44 (d, J = 8.5 Hz, 6H), 7.28 (t, J = 7.8 Hz, 6H), 7.21 (t, J = 7.3 Hz, 3H), 
3.17 (t, J = 7 Hz, 2H), 3.04 (t, J = 6.5 Hz, 2H), 1.80 (quint, J = 7.3 Hz, 2H), 1.61 
(quint, J = 7 Hz, 2H), 1.35 (br, 4H), 1.26–1.40 (br, 10H); 13C NMR (125 MHz, 
CDCl3) δ 144.6, 128.7, 127.7, 126.8, 86.3, 63.7, 33.6, 30.5, 30.1, 29.5, 29.4, 28.5, 
26.3, 7.3. 
Diethyl 10-triphenylmethoxydecylphosphonate (3) 
A solution of 2 (9.33 g) in triethyl phosphite (7.5 mL) was brought to reflux at 165oC 




was chromatographed on silica gel (33% EtOAc:hexanes-100% EtOAc) to give 5.3 
g of a colorless oil (yield = 56%): 1H NMR (500 MHz, (CD3)2CO) δ 7.44 (d, J = 7.5 
Hz, 6H), 7.28 (q, J = 6.8 Hz, 6H), 7.22 (t, J = 7.5 Hz, 3H), 4.03–4.15 (m, 5H), 3.03 
(t, J = 6.5 Hz, 2H), 1.67–1.75 (m, 2H), 1.53–1.64 (m, 4H), 1.29–1.39 (m, 11H), 
1.20–1.29 (m, 8H); 13C NMR (125 MHz, CDCl3) δ 144.5, 128.7, 127.7, 126.8, 86.3, 
63.7, 61.4, 61.3, 30.7, 30.6, 30.0. 29.5, 29.4, 29.1, 26.3, 25.1, 22.4, 16.5, 16.1 
Diethyl 10-hydroxydecylphosphonate (4) 
Compound 3 (2.3 g) was dissolved in THF (19 mL) and HCl (2 mL) and stirred 
overnight. The mixture was neutralized with 1 M NaHCO3 and extracted with DCM 
(3 x 20 mL). The organic fractions were combined and washed with 1 M NaHCO3 
and brine and dried over Na2SO4. The solvent was removed in vacuo and the 
residue chromatographed on silica gel (33% EtOAc:hexanes-100% EtOAc-10% 
MeOH:EtOAc) to give 1.25 g of a colorless oil (yield = 99%): 1H NMR (500 MHz, 
CD3OD) δ 4.08 (quint, J = 5.6 Hz, 4H), 3.54 (t, J = 7.5, 2H), 1.79 (sextuplet, J = 7 
Hz, 2H), 1.54 (br, 4H), 1.29–1.43 (br, 18H). 
10-Diethoxyphosphonodecyl (2,5-dioxopyrrolidin-1-yl)carbonate (5) 
To a solution of 4 (547.6 mg) and DIEA (365 uL) in CH3CN (10.5 mL) was added 
disuccinimidyl carbonate (1011.1 mg). After stirring for 24 h at RT, the solvent was 
removed in vacuo. The residue was dissolved in EtOAc (10 mL) and washed with 
5% HCl (8 mL), dH2O (8 mL), and brine (10 mL). The washes were back-extracted 
with EtOAc (5 mL) and organic layers were combined before drying over Na2SO4. 
The solvent was removed in vacuo and the residue chromatographed on silica gel 




colorless oil (yield = 62%): 1H NMR (400 MHz, CDCl3) δ 4.32 (t, J = 7.2 Hz, 2H), 
4.09 (octuplet, J = 8 Hz, 4H), 2.84 (s, 4H), 1.74 (m, 4H), 1.60 (m, 2H), 1.29–1.43 
(m br, 18H); 13C NMR (100 MHz, CDCl3) δ 168.7, 151.6, 71.6, 61.4, 61.3, 30.6, 
30.5, 29.3, 29.2, 29.0, 28.3, 26.2, 25.4, 25.3, 25.1, 22.4, 22.3, 16.5, 16.4. 
10-((((2,5-Dioxopyrrolidin-1-yl)oxy)carbonyl)oxy)decyl)phosphonic acid 
A solution of 5 (841 mg) in DCM (10 mL) was cooled to 0oC. To this was added 
bromotrimethylsilane (1 mL) with stirring for 15 min, at which point the mixture was 
warmed to RT and allowed to stir overnight. The solvent was removed in vacuo 
and the oily residue was dissolved in 1:1 H2O/acetone (15 mL) and stirred for 4 h. 
The mixture was extracted with DCM (3 x 10 mL). Organic fractions were 
combined, washed with brine, and dried over Na2SO4. The solvent was removed 
in vacuo to give 578 mg of white solid that was used without further purification: 




A solution of 10-((((2,5-Dioxopyrrolidin-1-yl)oxy)carbonyl)oxy)decyl)phosphonic 
acid (578 mg) and 4-(Boc-aminomethyl)benzyl alcohol (402 mg) in tetrahydrofuran 
(5 mL) was heated to reflux at 75oC. To this was added a solution of N,N’-
dicyclohexyl carbodiimide (360 mg) in tetrahydrofuran (4 mL) over a period of 2 h. 
This was stirred for 24 hours, after which point the reaction was cooled to RT and 
filtered through a celite pad to remove the insoluble urea byproduct. The filtrate 




detection) to give 155 mg of a colorless oil (yield = 17% over two steps): 1H NMR 
(500 MHz, CD3OD) δ 7.32 (d, J = 8 Hz, 2H), 7.26 (d, J = 4.5 Hz, 2H), 4.98 (d, J = 
9 Hz, 2H), 4.31 (m, 4H), 2.82 (s, 4H), 1.73 (m, 4H), 1.60 (m, 2H), 1.45 (s, 9H), 
1.30–1.40 (br, 4H), 1.23–1.30 (br, 9H); 13C NMR (125 MHz, CDCl3) δ 168.7, 151.6, 
139.1, 135.5, 135.4, 128.0, 127.5, 71.6, 66.1, 66.0, 44.3, 30.5, 30.4, 29.3, 29.2, 
29.0, 28.4, 28.3, 26.5, 25.4, 25.3, 22.2, 22.1; 
tert-butyl (4-((((10-((((2,5-dioxopyrrolidin-1-
yl)oxy)carbonyl)oxy)decyl)fluorophosphonyl)oxy)methyl)benzyl)carbamate 
A solution of 7 (20.9 mg) in DCM (0.5 mL) was cooled to 0oC and to it was added 
diethylaminosulfur trifluoride (14 uL). The reaction was stirred for 15 min at 0oC 
and 30 min at RT. Then was added ice-cold 1 M NaHCO3 (0.15 mL) and the two 
phases were stirred for 5 min at RT. The phases were separated, and the organic 
layer was washed with brine and dried over Na2SO4. The solvent was removed in 
vacuo to give 21 mg of a colorless oil which was used without further purification: 





To solution of 8 (21 mg) and DIEA (8 uL) in DMSO (0.35 mL) was added 5/6 mixed 
isomer TAMRA-cadaverine conjugate (20 mg, Biotium). After stirring at RT 
overnight, the reaction was diluted in MeCN and purified by preparative LC (0.2–




lyophilization to yield 12 mg of pink oil (yield = 34% over two steps): 1H NMR (500 
MHz, CD3OD) δ 8.66 (s, 0.5H due to mixed-isomer preparation), 8.28 (d, J = 8 Hz, 
0.5H due to mixed-isomer preparation), 7.83 (m, 0.5H due to mixed-isomer 
preparation), 7.35 (m, 1H), 7.30 (m, 1H), 7.26 (s, 4H), 7.17 (d, J = 9.5 Hz, 1H), 
6.85 (dd, J = 2.5, 9.5 Hz, 1H), 6.73 (m, 1H), 5.15 (m, 2H), 4.92 (br, 2H), 4.32 (br, 
1H), 4.02 (br, 1H), 3.52 (m, 1H), 3.26 (d, J = 12.5 Hz, 6H), 3.17 (br, 2H), 2.66–2.99 
(br, 12H), 2.35 (t, J = 7.5, 1H), 1.89 (m, 1H), 1.71 (m, 2H), 1.52–1.66 (br, 4H), 
1.40–1.50 (br, 6H), 1.15–1.40 (br, 13H), 0.78–0.92 (m, 2H); 31P NMR (125 MHz, 
CD3OD) δ 35.2, 29.8; 19F NMR (125 MHz, CD3OD) δ -75.7; HRMS [M+H]+ m/z 





Compound 7 (2 mg) was added to a solution of 25% TFA in DCM and stirred for 4 
h at RT. The reaction was diluted in MeCN and purified by preparative LC (0.2–
90% MeCN:H2O gradient, 500 nm detection). The solvent was subsequently 
removed by lyophilization to yield 1.4 mg of pink oil (yield = 70%): HRMS [M+H]+ 
m/z 900.4471 (calcd.), 900.4462 (found). 
10-(Diethoxyphosphoryl)decyl but-3-yn-1-ylcarbamate (9) 
To solution of 5 (790 mg) and DIEA (0.35 mL) in Et2O (10 mL) was added 1-amino-
3-butyne (0.165 mL), leading to rapid precipitation of N-hydroxysuccinimide as a 




The crude product was dissolved in 1:1 EtOAc:hexanes (3 mL) and 
chromatographed on silica gel (50–100% EtOAc:hexanes) to yield 615 mg of 
colorless oil (yield = 87%): 1H NMR (500 MHz, CDCl3) δ 4.87 (s, 1H), 4.04–4.13 
(m, 6H), 3.29 (q, J = 5 Hz, 2H), 2.25 (td, J = 10, 5 Hz, 2H), 1.98 (t, J = 1.7 Hz, 1H), 
1.68–1.76 (m, 4H), 1.44–1.66 (br, 4H), 1.25–1.41 (br, 18H) 
(10-((But-3-yn-1-ylcarbamoyl)oxy)decyl)phosphonic acid 
A solution of 9 (223 mg) in DCM (5 mL) was cooled to 0oC. To this was added 
bromotrimethylsilane (0.3 mL) with stirring for 15 min, at which point the mixture 
was warmed to RT and allowed to stir overnight. The solvent was removed in 
vacuo and the oily residue was dissolved in 1:1 H2O:acetone (10 mL) and stirred 
for 4 h. The mixture was extracted with DCM (3 x 5 mL). Organic fractions were 
combined, washed with brine, and dried over Na2SO4. The solvent was removed 
in vacuo to give 214 mg of white solid that was used without further purification: 




A solution of (10-((But-3-yn-1-ylcarbamoyl)oxy)decyl)phosphonic acid (214 mg) 
and 4-(Boc-aminomethyl)benzyl alcohol (172 mg) in tetrahydrofuran (1 mL) was 
heated to reflux at 75oC. To this was added a solution of N,N’-dicyclohexyl 
carbodiimide (160 mg) in tetrahydrofuran (3 mL) over a period of 1.5 h. This was 
stirred for 24 h, after which point the reaction was cooled to RT and filtered through 




purified by preparative LC (0.2–90% MeCN:H2O gradient, 254 nm detection) to 
give 67 mg of a colorless oil (yield = 19% over two steps): 1H NMR (500 MHz, 
CDCl3) δ 7.32 (d, J = 8 Hz, 2H), 7.25 (d, J = 8 Hz, 3H), 4.99 (d, J = 7.5 Hz, 2H), 
4.29 (s, 2H), 4.04 (m, 3H), 3.33 (t, J = 6.75 Hz, 2H), 2.40 (td, J = 3, 7 Hz, 2H), 2.00 
(t, J = 2.5 Hz, 1H), 1.67–1.79 (m, 3H), 1.54–1.66 (m br, 5H), 1.46 (s, 9H), 1.21–
1.39 (br, 15H); 13C NMR (125 MHz, CDCl3) δ 156.6, 135.5, 128.0, 127.6, 69.9, 
65.9, 65.8, 65.1, 30.5, 30.4, 29.4, 29.2, 29.2, 29.0, 28.4, 26.5, 25.8, 25.4, 22.2, 




A solution of 10 (107 mg) in DCM (1.5 mL) was cooled to 0oC and to it was added 
diethylaminosulfur trifluoride (52 uL). The reaction was stirred for 30 min at 0oC. 
Then was added ice-cold 5% w/v NaHCO3 and the two phases were stirred for 15 
min at RT. The phases were separated and the aqueous layer was extracted with 
DCM (3 x 1 mL). Organic layers were dried over Na2SO4, and the solvent was 





ylcarbamate (81 mg) was dissolved in 33% TFA in DCM. After 1 h, the solvent was 




frozen, and lyophilized to give a fluffy white solid. The solid was reconstituted with 
methanol and purified by preparative LC to yield 72 mg of white solid after 
lyophilization (yield = 73%): 1H NMR (500 MHz, CDCl3) δ 7.47 (s, 4H), 5.21 (d, J = 
9 Hz, 2H), 4.09 (s, 2H), 4.03 (t, J = 6.8 Hz, 2H), 3.35 (s, 1H), 3.29 (t, J = 6.75, 2H), 
2.39 (td, J = 3, 7 Hz, 2H), 2.10 (t, J = 2.8 Hz, 1H), 1.92–2.02 (m, 2H), 1.56–1.73 
(m, 5H), 1.38–1.46 (br, 2H), 1.25–1.38 (br, 10H); 13C NMR (125 MHz, CDCl3) δ 
133.2, 128.9, 128.5, 67.6, 67.5, 42.6, 39.3, 29.9, 29.8, 29.1, 28.9, 28.7, 28.6, 25.5, 
21.5, 21.4, 19.3; HRMS [M+H]+ m/z 455.2469 (calcd.), 455.2469 (found). 
Biological Materials and Equipment 
 Valacyclovir hydrochloride, acyclovir, and AEBSF were purchased from 
Sigma-Aldrich (St. Louis, MO) and used without further purification. FP-PEG-biotin 
and FP-TAMRA were prepared by Dr. Hao Xu according to previously reported 
procedures.48,50 Recombinant BPHL was prepared and generously gifted by Dr. 
Longsheng Lai. Pooled human intestinal S9 was purchased from Sekisui 
XenoTech (Lawrence, KS). SDS-PAGE Tris-glycine running buffer (10x), loading 
buffer (2x), NuPAGE™ reducing agent (10x), and polyacrylamide gels (8 x 8 x 0.1 
cm) were purchased from ThermoFisher (Waltham, MA). For cell culture 
experiments, all media and supplements were purchased from ThermoFisher. 
Phosphate-buffered saline pH 7.4 (PBS) was purchased from Gibco 
(ThermoFisher). 
Cell Culture 
The human colon carcinoma cell line Caco-2 (ATCC, HTB-37) was 




Minimum Essential Medium with 10% heat-inactivated fetal bovine serum, 1% 
penicillin-streptomycin and glutamine in 5% CO2 at 37°C. After washing with ice-
cold PBS (pH 7.4), cells were harvested by scraping and immediately 
homogenized by probe sonication on ice. Crude lysates were first spun at 9000 g 
for 20 min, yielding the S9 fraction which was further spun at 100000 g for 1 h. The 
supernatant was used as the cytosolic fraction (S100), while the pellet was 
resuspended in PBS with 0.1% v/v Triton X-100 and used as the membrane 
fraction (P100). Protein concentrations were determined by BCA assay, after 
which aliquots of lysate were stored at -80°C until use. 
Animals 
 Animal studies were conducted in accordance with the Guide for the Care 
and Use of Laboratory Animals as adopted and promulgated by the U.S. National 
Institutes of Health. Bphl-KO mice (pure C57BL/6 strain) were a generous gift from 
the Institut Clinique de la Souris (Illkirch Cedex, France) and were validated by 
genotyping. Gender-matched mice (pure C57BL/6 strain), 8–10 weeks old, were 
used in all the following procedures. The mice were kept in temperature-controlled 
housing with a 12/12-h light/dark cycle and received a standard diet and water ad 
libitum as provided by the Unit for Laboratory Animal Medicine, University of 
Michigan, Ann Arbor, MI. 
Lysate Preparation 
 One WT and one KO mouse, both male, were sacrificed by cervical 
dislocation and immediately dissected. The liver and jejunal segment were excised 




were cut into smaller pieces by razor and Dounce homogenized on ice. Crude 
lysates were spun 20 min at 9,000 x g and 4 °C, and the supernatant S9 fractions 
were centrifuged for another 60 min at 100,000 x g and 4 °C. The supernatant was 
used as the soluble fraction (S100), and the pellet was resuspended in PBS with 
0.1% Triton X-100 and used as the membrane fraction (P100). Lysates were 
aliquoted and stored at –80 °C until use. 
VACV Activation Probe Inhibition Assay 
Caco-2 lysate or Bphl-KO mouse jejunum/liver lysate (all 1 mg/mL) in PBS 
(pH 7.4) or rBPHL (0.2 μg/mL) in PBS with 0.1% w/v bovine serum albumin (BSA) 
was pretreated with inhibitors or vehicle at RT at least 30 min prior to reaction 
initiation. Reactions were preheated at 37°C for 3 to 5 min, at which point VACV 
was added to a final concentration of 1 mM to initiate the reaction. At 5, 10, and 15 
min post-initiation, aliquots of the reaction were quenched in two to four volumes 
of chilled organic solvent (acetonitrile or methanol) with 0.1% v/v trifluoroacetic 
acid (TFA). Precipitated protein was pelleted at 14000 g for 5 min, with the 
supernatant analyzed on Agilent 1100 Series HPLC equipped with a reverse-
phase Zorbax Eclipse XDB-C18 column (4.6 x 150 mm, 3.5 μm particle size). A 
binary solvent gradient from 2% to 90% MeCN in ddH2O (both with 0.1% TFA) with 
1.0 mL/min flow rate was used for separation with UV-based detection at 254 nm. 
External standards were used to determine the linear range of VACV and ACV 
while relative peak areas were used to calculate hydrolytic activity. To account for 





Optimization of In-Gel Probe Labeling Conditions 
Caco-2 lysate (1 mg/mL) in PBS (pH 7.4) was incubated with AMB-FP-
TAMRA (5 or 0.5 μM) at RT. At predetermined time points, an aliquot of the 
reaction was quenched in 1.25 volumes of 2x SDS loading buffer and 0.25 volumes 
of 0.5 M dithiothreitol. After heating to 90°C for 10 min, 15 μL per sample was 
electrophoresed in a Tris-glycine buffer system 226 V for 45 to 50 min. 
BenchMark™ Fluorescent Protein Standard (Invitrogen) was used for crude 
molecular weight determination. Gels were scanned on a Typhoon 9200 variable 
mode imager (Amersham) using 580 nm bandpass emission filter for TAMRA. 
In-Gel Probe Target Comparison in Caco-2 
Caco-2 lysate (1 mg/mL) in PBS (pH 7.4) was pretreated with inhibitor (FP-
PEG-biotin or AMB-FP-alk) or vehicle at RT at least 30 min prior to labeling. FP-
TAMRA (2 or 5 μM) or AMB-FP-TAMRA (5 or 10 μM) was added and allowed to 
label lysates for 30 min, at which point the reaction was quenched with 1.25 
volumes of 2x SDS loading buffer and 0.25 volumes of 0.5 M dithiothreitol. After 
heating to 90°C for 10 min, 15 μL per sample was electrophoresed in a Tris-glycine 
buffer system 226 V for 45 to 50 min. BenchMark™ Fluorescent Protein Standard 
(Invitrogen) was used for crude molecular weight determination. Gels were 
scanned on a Typhoon 9200 variable mode imager (Amersham) using 580 nm 
bandpass emission filter for TAMRA. 
In-Gel Probe Target Comparison in Cell/Tissue Lysates 
FP-TAMRA (5 μM) or AMB-FP-TAMRA (10 μM) was incubated in either 




or human intestinal S9 (all 1 mg∙mL-1) at RT. After 30 min, the reactions were 
quenched in 1.25 volumes of SDS loading buffer and 0.25 volumes of dithiothreitol 
(50 mM). Samples were heated to 90 °C for 10 min, and 15 μL per sample were 
electrophoresed on a 4–20% crosslinker gradient gel at 226 V for 50 min. 
BenchMark™ Fluorescent Protein Standard (ThermoFisher) was used for 
approximate molecular weight determination. Gels were scanned using a 580 nm 
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Identification and Validation of Candidate VACV PAEs by cABPP 
Introduction
Despite the well-established uses of cABPP for inhibitor profiling, substrate-
based cABPP is not as commonplace. One reason may be the kinetic 
considerations that must be accounted for to observe competition. Reversible 
ligands and inhibitors already require more careful optimization of reaction 
conditions to observe competition than do covalent inhibitors; the added factor of 
enzymatic turnover makes substrate competition even more sensitive to reaction 
conditions since substrate concentrations are steadily decreasing. The kinetic 
behavior of covalent inhibitors can be described by both a reversible binding 
component, KI, and a covalent inactivation component, kinact,51 analogous to the 
Michaelis-Menten kinetic parameters KM and kcat, respectively (Figure 3.1). Non-
specific organophosphonate inhibitors tend to have low binding affinity (i.e. high 
KI) but rapidly inactivate their target upon binding (i.e. high kinact).52 Consequently, 
high substrate concentrations or substrates with low KM and/or low kcat are 
advantageous when detection of competition is desired. Alternatively, probes with 





Figure 3.1. Mechanistic model of competitive irreversible inhibition. 
In single-binding interactions, substrate and covalent inhibitor compete for free enzyme resulting in 
either substrate occupancy, whose equilibrium is described by the concentration KM, or inhibitor 
occupancy, described by the analogous concentration KI. The second step is the irreversible 
conversion to product, which for substrates leads to product and regenerates the enzyme, 
described by the rate constant kcat. For covalent inhibitors, the enzyme is part of the product, a 
covalent complex with the inhibitor, and is not regenerated, which is kinetically described the by 
the analogous rate constant kinact.  
In addition to optimizing reaction conditions, another challenge in substrate 
cABPP is presented by the turnover byproducts, which, if allowed to accumulate, 
can themselves compete with probe labeling, confounding the results if only gel 
readout is used. After controlling for this, validation is still required to confirm that 
the enzymes engaged by the substrate are turning them over, not simply being 
inhibited. These considerations are minor, however, given the simplicity and speed 
with which cABPP elucidates the number and identity of candidate enzymes with 
the sought-after activity. For prodrugs whose activating enzyme is not readily 
determined by cursory reaction phenotyping methods, e.g. lisdexamfetamine,54 
cABPP could vitally aid in this effort. 
 Among the most useful technological developments of ABPP in the field of 




chemistry functionalities, especially azides and alkynes, to ABPs.55 Such low-
molecular weight and biologically inert moieties enhance the cell permeability and 
stability of ABPs and enable target identification and selectivity/potency evaluation 
in more physiologically relevant systems such as intact cells or preclinical 
organisms. Moreover, the relatively small azide and alkyne functionalities 
minimally alter the physicochemical properties and binding affinities of ABPs, 
especially those derived directly from pharmacological inhibitors. When combined 
with stable isotope labeling methods like SILAC,56 in which cells are grown in 
media supplemented with isotopologic amino acids, thus incorporating labels by 
normal metabolic protein turnover, click-based ABPP is a powerful tool for MS-
based identification, and quantitation of even subtle changes in enzyme activity 
directly within cells—a boon for pharmacological characterization of both enzymes 
and their modulators in pharmaceutical research and development. 
While most biotinylated ABPs are chemically stable, the biotinylated version 
of AMB-FP, which was able to be synthesized in small quantities (~1 mg), was not 
stable during storage for reasons that have not been explored. To circumvent this, 
AMB-FP-alkyne was treated under standard click-CuAAC conditions, with biotin-
(PEG)3-azide in organic solvent to pre-generate a biotinylated probe for use in 
cABPP-MS experiments. Unfortunately, this probe was also unstable in storage, 
so AMB-FP-alkyne itself was employed in MS-based cABPP experiments. This 
required extra handling steps, including a desalting step, a click chemistry step, 
and a precipitation clean-up step, all of which were likely to increase the variability 




aforementioned sensitivity to kinetic endpoints. We thus used stable isotope 
labeling using amino acids in cell culture (SILAC) to mitigate this issue, which was 
a major advantage in using cultured cells for the protein source instead of ex vivo 
tissue samples. Briefly, one cell population is grown in normal media (“light” cells) 
while another is grown in media containing heavier Arg and Lys isotopologs 
(“heavy” cells), which are essential amino acids, unable to be synthesized by the 
cell otherwise. After several rounds of division, the cellular proteome is labeled in 
its entirety with the respective Arg and Lys. After lysis and treatment with variable 
or control conditions, the heavy and light samples can be combined in a 1:1 ratio, 
such that all subsequent handling steps affect both samples equally. This 
minimizes these extraneous sources of variability, enabling more faithful detection 
of the effect of the experimental variable itself. To control for potential baseline 
differences in protein abundance or activity levels between cell populations, 
treatment and control conditions are applied to both heavy and light proteomes in 
a reciprocal manner. 
In addition to kinetic optimization, adaptation of the gel-based cABPP 
protocol to an MS-friendly format required the proper selection of sample clean-up 
techniques and redissolution buffers. An acetone quench/wash step was critical to 
providing a well-defined endpoint to the competition reaction while simultaneously 
removing excess probe. Subsequently, a redissolution buffer with high urea and 
ammonium bicarbonate concentrations was used to dissolve the sample pellets 
with bath sonication and heating to prepare for solution-phase click chemistry. 




accomplished by desalting spin columns. SDS, which also impedes CuAAC,57 is 
not efficiently removed by size-exclusion desalting columns when above its critical 
micellar concentration and was thus omitted from the redissolution buffer. These 
modifications were critical to translating the gel-based cABPP workflow to an MS-
compatible format that could also incorporate CuAAC. The use of MS-based 
cABPP with substrates is not described in the literature, let alone for the 
identification of PAEs. 
After identifying three candidate VACV PAEs via cABPP-MS, selective 
inhibitors were used to validate their activity directly in Caco-2 lysates. Only 
emetine, a selective inhibitor of RBBP9,58,59 showed any effect, abolishing 95% of 
VACV activation in Caco-2 S100 at selective concentrations. At the same 
concentration, emetine only inhibited 17% of VACV hydrolysis by rBPHL. An 
emetine-competitive ABPP-MS assay was also performed in Caco-2 S100 to 
ensure that emetine does not inhibit other SHs at 1 mM. Thus, the near-total 
inhibition of VACV activation in the presence of selective emetine concentrations 
suggests that RBBP9 may contribute more to gut wall activation of VACV than 
rBPHL. In addition to identifying RBBP9 as the second likely presystemic PAE for 






In-Gel Kinetic Optimization of cABPP 
 
Figure 3.2. Optimization of competition time via gel-based cABPP. 
A fluorescent gel scan of VACV-competitive labeling of Caco-2 S100 by AMB-FP-TAMRA (5 μM) 
at timepoints from 1 to 30 min. Red arrows show VACV-sensitive bands. 
 Saturating concentrations of VACV (20 mM) were used to compete against 
AMB-FP-TAMRA labeling in Caco-2 S100, with reactions stopped at various 
timepoints from 1 to 30 min. Three bands, whose molecular weights were 
interpolated to 100, 85, and 40 kDa (Figure 3.2, red arrows), were visibly sensitive 
to VACV, but each one displayed maximal competition at a different timepoint, 
highlighting the diverse reactivities within the serine hydrolome. The 8 min 
timepoint was chosen for subsequent studies based on the observation of 
competition for all three bands, which was confirmed by integration. The 
experiment was then repeated with 8 min competition using freshly prepared Caco-




sensitive band near 25 kDa (Figure 3.3, red arrows). The P100 fraction displayed 
one 100 kDa band that was more active in the presence of VACV, but none that 
were less active after VACV treatment, consistent with prior data from our lab 
which showed around 90% of intestinal VACV activation occurred in the soluble 
proteome (not shown). These data demonstrate the utility of substrate-based 
cABPP and the ease with which preliminary screens can be carried out to 
determine its feasibility for PAE identification on a case-specific basis. 
 
Figure 3.3. Gel-based cABPP with VACV in freshly prepared Caco-2 lysates. 
Representative fluorescent gel scan of 20 mM VACV-competitive labeling by AMB-FP-TAMRA (5 




VACV Target Identification by cABPP-SILAC 
 
Figure 3.4. VACV cABPP-SILAC in Caco-2 S100. 
SILAC enrichment ratios from VACV-competitive ABPP in Caco-2 S100 using 20 mM VACV and 
20 μM AMB-FP-alkyne. Results are shown as geometric mean with geometric SD factors (n = 3–
4). Checkered bars denote enzymes whose mean and SD factor product is less than one (“hits”). 
 Three SHs with reduced labeling in the presence of VACV were detected 
by LC-MS/MS (Figure 3.4, checkered bars): RBBP9, PPME1, and PPCE. The 
MWs predicted from the primary sequences of these candidate VACV PAEs were 
within 1–4 kDa of the MWs observed in-gel, except for the 100 kDa band. These 
discrepancies could be due to post-translational modifications or alternative 
splicing. Notably, RBBP9 labeling was completely inhibited by VACV incubation, 
essentially undetectable in all treatment samples. Such results were 
representative of prior non-SILAC cABPP-MS experiments in Caco-2 S100, 




In Vitro Validation of RBBP9 Activation of VACV 
 
Figure 3.5. Validation of RBBP9 as VACV PAE by emetine inhibition. 
Inhibition of VACV activation in Caco-2 S100 and rBPHL by selective RBBP9 inhibitor emetine at 
two concentrations. Emetine was not assayed against rBPHL at 33 μM. Results are shown as mean 
± SD (n = 3). **p < .01 and ***p < .001 by unpaired t-test as compared to respective controls at 0 
μM. 
To validate the VACV PAEs found by MS-based cABPP, selective inhibitors 
for all three hits were purchased and tested in Caco-2 S100. ABL127, a selective 
inhibitor of PPME1 with an IC50 of 6–12 nM (Ki not determined),60 produced no 
detectable inhibition of VACV activation at 100 nM; neither did selective PPCE 
inhibitor N-benzyloxycarbonyl-L-prolyl-L-prolinal at 10 nM, ten times its Ki of 1 nM.61 
Emetine, a commercially available natural product alkaloid found in ipecac syrup, 
was recently found to selectively inhibit RBBP9 at concentrations up to 33 μM,59 
with gel-based ABPP showing selectivity up to 1 mM in certain RBBP9-doped 
proteomes.58 At 33 μM, roughly four times the IC50 of 7.8 μM (Ki not determined), 
emetine inhibited ~40% of VACV activation in Caco-2 S100 (Figure 3.5). At 1 mM, 
emetine abolished VACV activation (~95%), confirming RBBP9’s VACV activation. 
Because emetine selectivity was established using FP-based assays that cannot 




emetine, and only 17% inhibition was observed. Based on these data, RBBP9 
appears to contribute more to VACV activation than does BPHL in Caco-2 S100. 
Notably, VACV represents the first reported substrate of RBBP9, synthetic or 
otherwise. 
Emetine Target Identification by cABPP-SILAC 
Uniprot ID Enrichment Ratio (SD Factor) 
CPVL 0.295 (3.16) 
LYPA2 0.410 (1.41) 
PPME1 0.474 (1.13) 
Table 3.1. Targets from emetine cABPP-SILAC assay. 
A list of SH enzymes in Caco-2 S100 whose labeling by AMB-FP-alkyne (20 μM) was significantly 
reduced in the presence of 1 mM emetine. 
 To more confidently conclude from emetine inhibition data that RBBP9 is a 
VACV PAE, we performed a cABPP-MS assay with 1 mM emetine in Caco-2 S100 
(Table 3.1). Prior studies of emetine selectivity were carried out in other cell and 
tissue lysates, but not in Caco-2. The results revealed three targets of emetine: 
lysophospholipase 2 (LYPA2), protein phosphatase methylesterase 1 (PPME1), 
and vitellogenic-like carboxypeptidase (CPVL). Of them, LYPA2 and CPVL were 
not shown to be targets of VACV by cABPP-MS. On the other hand, PPME1 was 
shown to be a target of VACV but was subsequently shown not to activate VACV 
when ABL127 incubation did not alter its hydrolysis rate in lysates. In conclusion, 
emetine, at the 1 mM concentration used for validation, does not target any 







 Optimizing one cABPP assay for MS-based readout led to the identification 
of a new VACV PAE without any a priori knowledge, demonstrating the true power 
of the broad survey enabled by ABPs compounded by state-of-the-art proteomic 
MS instrumentation and software. Validating the hits after their identification also 
obviated the need for special controls to address the confounding factor of product 
inhibition. The validation yielded negative results for the enzymes PPCE and 
PPME1, suggesting that they are merely binding partners of VACV and not its 
PAEs. Emetine itself has been well characterized for selectivity within the SH 
family by ABPP. In conjunction with the observation that AEBSF abolishes VACV 
activation in Caco-2, it is highly likely that the inhibition of VACV activation by 
emetine is almost solely the result of RBBP9 inhibition. However, it must be noted 
there are a handful of reports of sulfonyl fluoride inhibition of non-SH enzymes,62 
so the inhibition of non-SH enzymes by emetine in Caco-2, though unlikely, cannot 
be definitively ruled out. Though well-characterized inhibitors were used in this 
study, another potential validation method would be immunoprecipitating the 
proteins of interest, entailing the use of well-characterized antibodies instead. 
 
Scheme 3.1. Comparison of emetine and AMB moiety. 
Structure of emetine (X = Me) and cephaeline (X = H) with AMB-like motifs highlighted in red (left) 




A closer look at the structures of the AMB moiety and emetine reveals 
structural similarities that could explain the affinity of AMB-FP probes for RBBP9: 
an isomer of the AMB motif in which the positions of the oxygen and methylene 
group are interchanged is embedded twice within the structure of emetine with 
conformational restriction of the amino group (Scheme 3.1). In addition, the 6’-O-
desmethyl analog of emetine, cephaeline, is 3-fold less potent towards RBBP9.59 
The newly discovered VACV activating enzyme, RBBP9, has been studied 
in recent years with respect to cellular function, but repeated attempts to find a 
substrate for it, endogenous or synthetic, have failed.63 Named for its discovery as 
the ninth protein to bind the retinoblastoma tumor suppressor protein (Rb), this 
ubiquitously expressed protein was shown to be mandatory for suppression of the 
TGF-β antiproliferative pathway in vivo.64 This, in combination with its expression 
in several carcinoma cell lines and significantly elevated activity in pancreatic 
ductal adenocarcinoma samples,65 has led to the emergence of RBBP9 as a 
possible cancer drug target. Structurally, RBBP9 is ~21 kDa with a classic α/β 
hydrolase superfamily fold.66 Regarding primary structure, RBBP9 is quite distinct 
from other human proteins, with the closest being monoacylglyceride lipase (gene: 
MGLL) and, interestingly, BPHL, sharing ~15% sequence identity.63 The relative 
similarity to human BPHL may be a coincidence, but the overall uniqueness of the 
RBBP9 sequence suggests that there may be an opportunity for selectively 
targeting it. Furthermore, the homology between the human and mouse orthologs 




accurately reflect the in vivo disposition of therapeutics primarily metabolized by 






Biological Materials and Equipment 
 Valacyclovir hydrochloride, acyclovir, and emetine dihydrochloride were 
purchased from Sigma-Aldrich (St. Louis, MO) and used without further 
purification. AMB-FP-alkyne and AMB-FP-TAMRA were prepared as described in 
the preceding sections. FP-PEG-biotin and FP-TAMRA were prepared by Dr. Hao 
Xu according to previously reported procedures.48,50 Recombinant BPHL was 
prepared and generously gifted by Dr. Longsheng Lai. Recombinant RBBP9 was 
purchased from Novus Biologicals (Littleton, CO). For biological experiments (cell 
culture and gel electrophoresis), gels, buffers, and reagents/reagent kits were 
purchased from ThermoFisher (Waltham, MA). All compositional percentages are 
reported as v/v unless otherwise noted. Recombinant protein reactions were 
prepared in low protein-binding plasticware. Gels were electrophoresed on an 
XCell SureLock Mini-Cell electrophoresis system (ThermoFisher) with a PowerPac 
power supply adapter from Bio-Rad (Hercules, CA). Fluorescent gels were 
scanned on a Typhoon 9200 flatbed imager (Amersham, Boston, MA) and 
integrated using ImageJ software (NIH, Bethesda, MD). Analytical high-
performance liquid chromatography (HPLC) was performed on an Agilent 1100 
HPLC (Agilent, Santa Clara, CA) equipped with a reverse-phase Zorbax Eclipse 
XDB-C18 column (4.6 x 150 mm, 3.5 μm). The pH of phosphate-buffered saline 





The human colon carcinoma cell line Caco-2 (ATCC HTB37) was passaged 
at least six times and grown two weeks post-confluence in Dulbecco’s Minimum 
Essential Medium supplemented with 10% heat-inactivated fetal bovine serum, 1% 
penicillin-streptomycin and glutamine in 5% CO2 at 37 °C. Stable isotope-labeled 
Caco-2 cells were instead grown in lysine- and arginine-deficient SILAC-DMEM 
supplemented with 100 μg/mL “heavy” Arg (13C6, 15N4, +10 Da) and Lys (13C6, 15N4, 
+8 Da) or “light” Arg and Lys. After washing with ice-cold PBS, cells were harvested 
by scraping and immediately homogenized by probe sonication on ice. Crude 
lysates were first spun at 9,000 g for 20 min, yielding the S9 fraction, which was 
further spun at 100,000 g for 1h. The supernatant was used as the cytosolic 
fraction (S100), while the pellet was resuspended in PBS with 0.1% Triton X-100 
and used as the membrane fraction (P100). No protease inhibitors were used as 
this would interfere with subsequent studies of esterases. Protein concentrations 
were determined by BCA assay, after which lysates were aliquoted and stored at 
-80 °C until use. 
In-Gel Kinetic Optimization of cABPP 
 For kinetic optimization, Caco-2 S100 in PBS (1 mg/mL) was pretreated 
with VACV (20 mM) or vehicle for 5 min at RT, then incubated with AMB-FP-
TAMRA (5 μM) at RT. At 1, 3, 5, 8, 15, and 30 min post-initiation, aliquots were 
quenched in 1.25 volumes of SDS loading buffer and 0.25 volumes of 0.5 M 
dithiothreitol. Samples were heated to 90 °C for 10 min, and 15 μL per sample 




BenchMark™ Fluorescent Protein Standard (ThermoFisher) was used for 
approximate molecular weight determination. Gels were scanned using a 580 nm 
bandpass emission filter for TAMRA fluorescence. 
 After optimization, freshly prepared Caco-2 S100 and P100 fractions (both 
1 mg/mL) were pretreated with VACV (20 mM) or vehicle for 5 min at RT then 
incubated with AMB-FP-TAMRA (5 μM) at RT. After 8 min, aliquots were quenched 
in 1.25 volumes of SDS loading buffer and 0.25 volumes of 0.5 M dithiothreitol and 
subjected to the same electrophoresis and analysis as for kinetic optimization 
experiments. 
VACV Target Identification by cABPP-SILAC 
 Quadruplicate heavy and light Caco-2 S100 fractions (2 mg/mL, 1 mg total) 
were pretreated with VACV (20 mM) or vehicle for 2 min, followed by addition of 
AMB-FP-alkyne (20 μM). After 4 min, VACV-treated heavy (light) and untreated 
light (heavy) reactions were combined by quenching in the same aliquot of ice-cold 
acetone (4 mL). After chilling to -20 °C for 30 min, proteins were pelleted at 1,320 
g for 10 min. The pellet was washed twice more by sonication in fresh acetone and 
spun down again. After decanting and air-drying, the cleaned pellet was dissolved 
in 700 μL of PBS containing 8 M urea and 0.1 M ammonium bicarbonate with 
heating to 40 °C as needed.  
Samples were exchanged into 700 μL PBS using Zeba desalting spin 
columns (ThermoFisher). To each sample was then added tris(2-
carboxyethyl)phosphine (TCEP, 1 mM), tris[(1-benzyl-1H-1,2,3-triazol-4-




resulting in immediate formation of a blueish-hued precipitate. The click reaction 
proceeded for 1.5 h at RT, at which point samples were diluted with 4 mL MeOH, 
0.7 mL CHCl3, and 1.5 mL water, vortexed, and centrifuged 10 min at 1,300 g to 
separate aqueous and organic phases. Both phases were discarded, leaving 
behind the pellet, which was rinsed twice more by sonicating in an additional 4 mL 
MeOH and centrifuging.  
The biotinylated pellet was dissolved in 700 μL PBS containing 20 mg/mL 
SDS, 6 M urea, and 50 mM ammonium bicarbonate. Samples were then diluted to 
10 mL in PBS and incubated with 50 μL of prewashed (3 x 1 mL PBS) streptavidin-
agarose beads (ThermoFisher) for 1.5 h at RT with shaking. Beads were then 
collected by centrifugation for 2 min at 600 g and washed in PBS with 20 mg/mL 
SDS and 6 M urea (5 x 700 μL), water with 6 M urea (3 x 800 μL), and PBS (2 x 
800 μL). After transferring to low-protein binding microcentrifuge tubes, successive 
on-bead reduction and alkylation were carried out with iodoacetamide (25 mM, 30 
min, RT, dark) and TCEP (10 mM, 30 min, RT), respectively, in PBS with 2 M urea. 
On-bead digestion was performed overnight with 2 μg SOLu Trypsin (Sigma) in 
PBS at RT. Beads were spun down at 600 g for 1 min, and the supernatant was 
transferred onto Oasis C18 solid-phase extraction cartridges (Waters, Milford, MA) 
for desalting. Tryptic peptides were eluted in 1 mL 50% MeCN/water with 0.1% 
TFA and concentrated to dryness on a vacuum centrifuge. Before analysis, 




Emetine Target Identification by cABPP-SILAC 
 Duplicate heavy and light Caco-2 S100 fractions (2 mg/mL, 1 mg total) were 
pretreated with emetine dihydrochloride (1 mM) or vehicle for 2 min, followed by 
addition of AMB-FP-alkyne (20 μM). After 4 min, VACV-treated heavy (light) and 
untreated light (heavy) reactions were combined by quenching in the same aliquot 
of ice-cold acetone (4 mL). All subsequent steps are identical to those reported in 
the previous subsection (“Identification of VACV Targets by cABPP-MS”). 
Mass Spectrometry and Data Analysis 
Analysis was performed on a TripleTOF 5600 + mass spectrometer (AB 
Sciex, Framingham, MA) coupled with an Eksigent 2D plus LC system (Eksigent 
Technologies, Dublin, CA). A trap-elute configuration was used in the LC 
separation. It consisted of a trapping column (ChromXP C18-CL, 120 Å, 5 μm, 10 
× 0.3 mm, Eksigent Technologies, Dublin, CA) and an analytical column (ChromXP 
C18-CL, 120 Å, 150 × 0.3 mm, 5 μm, Eksigent Technologies, Dublin, CA). The 
mobile phase A was water containing 0.1% formic acid and mobile phase B was 
acetonitrile containing 0.1% formic acid. The sample was first loaded and cleaned 
on the trapping column with the mobile phase A delivered at 10 μL/min for 3 min 
before being separated on the analytical column with a gradient elution at 5 μL/min 
for 90 min. The gradient setting was: 0–68 min, 3%–30% B; 68–73 min, 30%–40% 
B; 73–75 min, 40%–80% B; 75–78 min, 80% B; 78–79 min, 80%–3% B; 79–90 
min, 3% B. A blank injection after each sample was used to prevent carryover.  
The mass spectrometer was operated in positive ion mode with ion spray 




at 25 psi and source temperature at 280 °C. A data-dependent acquisition method 
was used for data acquisition. It consisted of a 250 ms TOF-MS scan from 400 to 
1250 Da, followed by MS/MS scans in high sensitivity mode from 100 to 1500 Da 
for the top 30 precursor ions from the TOF-MS scan (50 ms accumulation time, 10 
ppm mass tolerance, charge state from +2 to +5, rolling collision energy, and 
dynamic accumulation). Former precursor ions were excluded from MS/MS scan 
for 15 s. 
The proteomics data were analyzed using MaxQuant software (version 
1.6.2.6, Max Planck Institute of Biochemistry, Germany). The UniProt human 
proteome AUP000005640 which includes both canonical and isoform protein 
sequences was used as the peptide search reference. Multiplicity was set as 2 
with 13C615N2-Lys and 13C615N4-Arg as heavy labels. “Trypsin/P” was set as 
the digestion enzyme. Peptide lengths were between 7 and 25 residues with up to 
two missed cleavage sites allowed. Cys carbamidomethylation was set as a fixed 
modification. Variable modifications included N-terminal acetylation and Met 
oxidation. Up to 5 modifications per peptide were allowed. Mass tolerance for 
precursor was 0.07 Da for the first search and 0.006 Da for the main search, while 
the tolerance for fragment ions was 40 ppm. A false discovery rate (FDR) of 0.01 
was used as the cutoff for both peptide and protein identification.  
For VACV-competitive ABPP, the enrichment ratio was calculated as the 
geometric mean of the ratios of SH intensities in treated samples to those of control 
samples. If one of the two intensity values in a SILAC pair was zero, it was treated 




was not detected in either sample of a SILAC pair), the undefined value was 
excluded from calculations. SHs with more than one undefined value were 
excluded. SHs were considered hits if the product of their mean ratio and SD factor 
was less than one whereas SHs were excluded if the product was greater than 10. 
For emetine-competitive ABPP, the enrichment ratio was calculated 
identically. If one of the two intensity values in a SILAC pair was zero, it was treated 
as one instead for calculation purposes. If both intensities were zero (i.e. the SH 
was not detected in either sample of a SILAC pair), the SH was excluded from 
consideration because only two SILAC pairs per SH, one in each direction, were 
assayed. SHs for which both SILAC ratios were less than one were considered 
targets of emetine. Data acquisition was performed by Dr. Jian Shi. 
In Vitro Validation of RBBP9 Activation of VACV 
 Caco-2 S100 (1 mg/mL) or purified recombinant hBPHL (0.2 μg/mL) in PBS 
in triplicate was incubated with emetine (0.33 or 1 mM) for 5 min at 37 °C. 
Reactions were initiated by the addition of VACV (1 mM) and were quenched 10 
min after initiation in four volumes of MeOH with 0.1% TFA. Proteins were pelleted 
for 5 min at 14,000 g, followed by analysis of the supernatant via HPLC. A binary 
solvent gradient from 2% to 90% acetonitrile in water (both with 0.1% TFA) with 
1.0 mL/min flow rate was used for separation. Analytes were detected by 
absorbance at 254 nm. Relative peak areas were used to calculate hydrolytic 
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In Vitro, Ex Vivo, and In Situ Characterization of RBBP9 Activity 
Introduction
 After the discovery of RBBP9 as a VACV PAE and the assignment of VACV 
as its first substrate, the next step was to characterize the substrate-enzyme 
interaction and investigate how this activity compared to that of BPHL. First was to 
examine the binding stoichiometry of VACV to RBBP9 by gel-based cABPP IC50 
determination to evaluate the applicability of the Michaelis-Menten model in further 
studies. Afterwards, a steady-state Michaelis-Menten model was derived from 
reaction velocity of RBBP9 VACV activation at eight VACV concentrations. This 
would provide an estimate of the catalytic efficiency of RBBP9, which can then be 
compared to that of BPHL for initial insight. The overall goal was to determine the 
relevance and estimate the relative contribution of RBBP9 presystemic VACV 
activation to the disposition of VACV in vivo, which would ideally be extrapolated 
from an in vitro model. In vitro models are highly desirable in the pharmaceutical 
industry for their simplicity, reproducibility, throughput, cost, and ethical 
advantages over in vivo models. However, their usefulness hinges on the strength 
of their correlation to in vivo metrics since they ultimately serve to predict important 
drug properties. 
Caco-2 cells, from which RBBP9 was identified as another PAE of VACV, 




drug absorption. They are well-known for expressing several clinically relevant 
transporters, including peptide transporter 1, PEPT1, organic anion transporting 
polypeptide 2B1, OATP2B1, breast cancer resistance protein, BCRP, and P-
glycoprotein, P-gp.68 Additionally, roughly two weeks after reaching confluence, 
Caco-2 cells differentiate into polarized cells with tight junctions, structurally 
resembling microvilli.69 However, with ester-bearing agents in particular, caution 
must be used in interpreting study results obtained from Caco-2 cells due to the 
differential expression patterns of CES isozymes as compared to actual human 
enterocytes.70 Specifically, CES1 is abundantly expressed in Caco-2 cells but is 
undetectable in the small intestine while CES2, which is the predominant isoform 
in the small intestine, is only expressed at low levels in Caco-2 cells. This is 
significant if one considers the remarkably different substrate specificities of the 
two isoforms, whereby CES1 prefers large acyl groups and small alcohol groups 
and CES2 prefers the opposite.71 Furthermore, RBBP9 has not been characterized 
to date in Caco-2 cells at the expression, abundance, or activity level. 
Thus, it was imperative that our results from VACV assays in Caco-2 with 
emetine inhibition be tested in another model that more convincingly approximates 
human in vivo conditions. Rodent models are well-characterized for several 
classes of therapeutic compounds and are universally utilized as preclinical 
species. Both rats and mice are known to highly express CES2 in the small 
intestine with CES1 essentially undetectable, similar to the human expression 
profile.72 Mice are also strongly preferred for the generation of gene-silenced 




modulators exist for a gene product, such as BPHL. Fortunately, Bphl-knockout 
(KO) mice were available for study, making reaction phenotyping of VACV with 
respect to both BPHL and RBBP9 feasible. First, lysates were prepared from the 
jejuna and livers of both WT and KO mice. The VACV activation in each of the four 
lysates was assayed with and without emetine. Finally, single-pass intestinal 
perfusions (SPIPs) of VACV were performed in WT mice with and without emetine 
pre-perfusion; unfortunately, KO mice were not old enough for inclusion at the time 
of study. Evaluation of VACV and ACV levels in the portal blood were carried out 
after 5 min of VACV perfusion to obtain a snapshot of presystemic activation.  
Results from the IC50 determination of VACV by gel-ABPP showed single-
binding stoichiometry, which justified kinetic characterization by Michaelis-Menten 
experiments. Overall affinity was ten-fold lower than BPHL, but catalytic efficiency 
was roughly half of BPHL. In spite of this, studies in WT and KO mouse lysates 
showed that RBBP9 could be activating VACV to a much greater extent than BPHL 
in the gut wall while the two were roughly equal activators of VACV in the liver. 
Perfusion data revealed that RBBP9 is involved in presystemic activation of VACV 







IC50 Determination of VACV vs. RBBP9 by Gel-Based ABPP 
 
Figure 4.1. VACV IC50 determination in rRBBP9. 
Concentration-response curve by gel-based cABPP of rRBBP9 with VACV and AMB-FP-TAMRA. 
Response was measured as fluorescent intensity. Data points were fitted to the Hill equation with 
a fixed slope of one by nonlinear least squares regression. 
One common application of gel-based ABPP in inhibitor profiling is the 
determination of IC50 values, where it is most useful for enzymes with no assigned 
substrates. Gel-based activity readouts are facile and rapid, with higher throughput 
than chromatographic methods, though not truly high-throughput in nature. This 
provides a fast way to estimate inhibitor potency or substrate affinity. A major 
shortcoming of the approach is that time-dependent probe inhibition results in an 
IC50 that changes depending on the competition time chosen for the assay, 
requiring some measure of optimization as with other cABPP assays. 
After optimizing the VACV-RBBP9 competition time at high VACV 
concentrations, the competition was performed with 11 concentrations of VACV 




VACV, the pH of the buffer begins to be affected by a nontrivial amount (>0.5 
units), so these were not tested. After plotting the activities against VACV 
concentrations and fitting the Hill equation by nonlinear least-squares regression, 
the IC50 was estimated to be 0.93 mM (Figure 4.1). The coefficient of determination 
(R2) of 0.67 indicates an acceptable fit that was substantially lowered by the 
variability at low VACV concentrations. This supported the single-binding 
stoichiometry of the RBBP9-VACV interaction, justifying the application of the 
Michaelis-Menten model for studying reaction kinetics. 
Steady-State Michaelis-Menten Kinetic Assay 
 
Figure 4.2. Michaelis-Menten kinetics of RBBP9 VACV activation. 
Plot of initial reaction velocity versus substrate concentration. Each data point represents the mean 
± SD of three independent determinations. All 24 points were fitted to the steady-state Michaelis-
Menten equation using nonlinear least squares regression. Parameters are shown with standard 
error. 
To compare the VACV hydrolytic activities of RBBP9 and BPHL, the first step was 




Menten model is often used for modeling single-substrate reactions. Based on the 
good approximation when using the Hill equation with a slope of one to estimate 
the IC50 of VACV against AMB-FP-TAMRA labeling of RBBP9, the assumption of 
a single-substrate reaction is likely valid and justifies the use of this model. 
 By plotting the initial reaction velocities of VACV hydrolysis by RBBP9 at 8 
concentrations from 250 to 2000 μM against the VACV concentration and fitting 
the Michaelis-Menten equation by nonlinear least-squares regression, the Vmax and 
KM were estimated to be 4.2 μM∙s-1 and 1.9 mM, respectively, translating to a kcat 
of 193 s-1, and a catalytic efficiency, kcat∙KM-1, of 104 mM-1∙s-1 (Figure 4.2). This is 
an average value relative to the distribution of known enzyme catalytic 
efficiencies73 but is comparable to the catalytic efficiency of 223 mM-1∙s-1 obtained 
for BPHL,31 which is higher mainly due to its greater affinity for VACV (KM = 0.19 
mM). 
Half-Life Determination of Valyl-Gemcitabine in rRBBP9 
 
Figure 4.3. Half-life determination of 5’-L-Val-gemcitabine in rRBBP9. 
The in vitro half-life of 5’-L-Val-gemcitabine was determined in rRBBP9 at 37 °C with data presented 




The immediate availability of 5’-L-Val-gemcitabine prompted us to test whether it, 
too, was a substrate of RBBP9 in the same way that it is a substrate of BPHL, 
which has been shown to be specific for α-amino acid esterases. The half-life of 
the prodrug in 5 μg∙mL-1 rRBBP9 at 37 °C was calculated to be 20-fold lower than 
the half-life in buffer at the same temperature (8 vs. 160 min), demonstrating that 
it is very likely a substrate (Figure 4.3). Further investigations into the substrate 
specificity of RBBP9 are warranted. 
VACV Hydrolysis Assay with Emetine in Mouse Tissue Lysates 
 
Figure 4.4. Emetine inhibition of VACV activation in WT and Bphl-KO mouse tissue lysates. 
VACV hydrolytic activity in various mouse tissue lysates with and without emetine (1 mM). Data are 
presented as mean ± SD of three technical replicates. ***p < .001 by unpaired t-test as compared 
to control of same tissue type or as noted by brackets. 
Due to the fact that Caco-2 cells may not be representative of the human intestinal 
mucosa specifically with respect to ester-based drugs, we sought to establish 
preliminary proof of relevance in mice, whose RBBP9 ortholog is highly identical 




experiments. Experiments in soluble tissue lysates of the liver and jejunum from 
both WT and KO mice with and without emetine yielded estimates of the 
contribution of each enzyme to presystemic VACV activation (Figure 4.4).  
Comparison of VACV hydrolysis in WT and KO lysates of the same tissue 
without emetine revealed the likely proportion of BPHL-dependent activation in that 
tissue. In the liver, KO lysates show roughly half the activity of WT, while jejunal 
KO samples were roughly equal in activity to the WT samples, implying that BPHL 
contributes significantly to hepatic activation of VACV but may be trivial with 
respect to intestinal activation. 
On the other hand, comparison of KO tissue lysate activities in the presence 
and absence of emetine revealed the likely proportion of RBBP9-dependent 
activation in that tissue. In both KO liver and jejunum samples, addition of emetine 
resulted in the near-total elimination of VACV activation, strongly implying that 
RBBP9 is the only presystemic VACV PAE in Bphl-KO mice. The difference 
between KO samples with and without emetine, when added to the same 
difference between WT samples, almost reconstitutes the entire activity of WT 
samples without emetine, signifying that RBBP9 and BPHL are essentially the only 




Single-Pass Intestinal Perfusions with and without Emetine 
Group [ACV] (μM) [VACV] (μM) [ACV + VACV] (μM) % Activated 
- EM (n = 6) 5.0 ± 1.1 1.8 ± 0.5 6.8 ± 1.6 73.8 ± 2.3 
+ EM (n = 8) 1.3 ± 0.2** 1.0 ± 0.2 2.2 ± 0.3** 58.4 ± 4.5* 
Table 4.1. Results of single-pass intestinal perfusions of VACV in WT mice. 
Results of single-pass intestinal perfusions of VACV (1 mM) in WT mice with and without emetine 
(EM) pre-perfusion presented as mean ± SEM. The sample numbers listed represent biological 
replicates in each group. *p < .05, ** p < .01 by Welch’s unequal variance unpaired t-test. 
SPIP studies are often carried out to study absorptive processes of drug 
candidates in isolation in a physiologically relevant system. Additionally, SPIP can 
be used to presystemic metabolism that takes place in the intestinal lumen by 
analyzing metabolite levels in the outlet perfusate. To assess presystemic 
metabolism taking place within the gut wall, however, sampling of the portal vein 
blood is required, which is the approach we chose to assess BPHL and RBBP9 
first-pass activity. With regards to analysis, a tradeoff exists between accuracy and 
analyzability due to the terminal nature of non-cannulated portal vein sampling: 
choosing a sampling timepoint that is too early results in analyte levels that could 
be below the limit of detection, while one that is too late captures a snapshot of 
metabolism that is convoluted by hepatic and systemic metabolism, distribution, 
and elimination. Emetine, which was historically used for its emetic effect to expel 
ingested poisons, is thought not to cause the same effect in rodents, and 
consistent with this notion, no emesis or GI disturbance was observed in our 
studies. 
Because our approach utilized UPLC analysis instead of the more sensitive 
LC-MS/MS, the concentration of VACV in the perfusion buffer was high (1 mM), 
taking advantage of the extremely high-capacity mouse PepT1 transporter that 




enabled the selection of a relatively quick 5 min sampling timepoint. The extended 
pre-perfusion of emetine (60 min) was informed by preliminary experiments to 
ensure the free intracellular emetine concentration is as high as possible prior to 
the addition of VACV. KO mice could not be used as they were not of sufficient 
age at the time of study, so only WT mice were used (six control mice, eight 
treatment mice). 
 
Figure 4.5. Single-pass intestinal perfusions of VACV in WT mice. 
Single-pass intestinal perfusion of VACV (1 mM) for 5 min in WT mice with and without emetine 
(EM) pre-perfusion. Portal vein blood was assayed for ACV and VACV by UPLC. Each data point 
represents the proportion of parent drug ACV detected in individual mice, with the group mean 
denoted by horizontal bars. *p < 0.05 by Welch’s unequal variance unpaired t-test. 
Emetine pre-perfusion resulted in a statistically significant (p < .05) 
decrease in pre-systemic VACV activation from 74 ± 2% to 58 ± 5%, representing 
a ~22% relative decrease in activation and a ~50% increase in unactivated prodrug 
levels (Figure 4.5). Interestingly, the amount of ACV detected was also significantly 
reduced (p < .01, Table 4.1) in the treatment group (1.3 ± 0.2 μM vs. 5.0 ± 1.1 μM), 
but the amount of VACV detected was not significantly different (1.0 ± 0.2 μM, 





 After validating the VACV hydrolytic activity of RBBP9 in Caco-2 lysates 
using the selective inhibitor emetine, the next step was to characterize the activity 
and establish relevance in mice with the goal of gathering evidence for clinical 
relevance. Caco-2 cells are heterogeneous, and genetic drift can lead to cell 
subpopulations with considerably different genotypes after repeated passaging.75 
Furthermore, Caco-2 cell esterases, such as CES1 and CES2, are at levels that 
are not representative of human enterocytes.70 Mice, on the other hand, better 
approximate humans in terms of presystemic ester metabolism.72,76,77 In addition, 
we had access to Bphl-KO mice for some of the experiments, allowing us to 
individually study the contributions of the two known VACV PAEs, BPHL and 
RBBP9. 
 To characterize the activity, gel-based ABPP IC50 studies of VACV against 
RBBP9 were performed to validate that the reaction was indeed a single-substrate 
reaction with only one enzyme binding site to justify application of the steady state 
Michaelis-Menten kinetic model for subsequent characterization. The estimated 
Hill slope magnitude of 0.81 was reasonably close to one, confirming the single-
binding stoichiometry, which was expected given the crystal structure of RBBP9 
revealing one active site.66 The Michaelis-Menten experiments yielded a Michaelis 
constant that was about tenfold below that of BPHL, though the turnover number 
was roughly five times that of BPHL, giving a catalytic efficiency that was just under 
half the value for BPHL. This indicates that RBBP9 is likely a lower affinity VACV 




 Upon scrutiny of the ex vivo experiments, it was confirmed that RBBP9 is 
likely the primary VACV PAE in the small intestine based on the observation that 
emetine, which selectively inhibits RBBP9, nearly completely extinguishes VACV 
hydrolysis in both WT and KO soluble jejunum lysates, with slight residual activity 
seen in the WT samples. The difference between baseline activities of WT and KO 
jejunal lysates was very little, further suggesting a diminutive contribution to VACV 
activation by BPHL in the tissue. In the liver lysates, the WT samples showed 
roughly equal contributions by both enzymes, given about half the activity 
remained after addition of emetine. In both tissues of the KO mice, emetine 
incubation nearly totally inhibited VACV activation, demonstrating that RBBP9 is 
likely the only other presystemic activating of enzyme upon deletion of BPHL. 
These activity data with respect to BPHL corroborate previously published results 
showing the tissue expression levels of BPHL in mice, in which 3–8 times the 
expression was detected in the liver than in any of the three segments of the small 
intestine.42 The same expression pattern is also seen in humans.78 
 In the follow-up in vivo experiments, emetine pre-perfusion significantly 
decreased presystemic intestinal VACV activation as monitored in the portal vein 
blood. Activation was calculated as the proportion of parent drug to total drug 
species (VACV and ACV), normalizing for any potential differences in VACV 
uptake or permeability that could be caused by emetine, e.g. by inhibition of 
PepT1. The long pre-perfusion of emetine was meant to deliver sufficiently high 
intracellular concentrations of emetine to effect RBBP9 inhibition, though this could 




group could be due to intracellular concentrations of emetine that are well below 
the in vitro concentrations that were used in the tissue lysate experiments or the 
significant activity of BPHL in the liver, which would be reflected in the data due to 
the 5 min sampling time being much longer than the 15 s blood circulation time in 
mice.79 In conclusion, the data obtained from SPIP experiments indicate that 
neither RBBP9 nor BPHL, individually, is obligatory for the presystemic conversion 
of VACV to ACV in vivo. 
 From these findings, it is clear that RBBP9 and BPHL in tandem, mediate 
the presystemic activation of VACV in vivo, with RBBP9-dominant activation in 
enterocytes and equally shared activation in the liver. Both BPHL and RBBP9 are 
highly identical between mouse and human orthologs, with BPHL also showing 
similar expression patterns between mouse and humans, ultimately suggestive of 
a similar VACV activation profile in humans. What remains to be studied, with 
respect to drug and prodrug development in particular, are the relative activity 
factors and substrate specificities of mouse, rat, and higher preclinical species 
enzymes as compared to the human enzymes to aid in preclinical model selection 
and allometric scaling/dose prediction. This would also empirically assist the 
rational design of RBBP9-targeted prodrugs, which could be further supported by 
computer-aided design. Additionally, genetic polymorphisms should be examined 
from individual genetic data, and the consequently discovered mutants should be 
generated and assayed for activity to appreciate the pharmacogenetic risks of 




agents might be assayed for activation/metabolism by RBBP9 to determine what 





Materials and Equipment 
 AMB-FP-TAMRA was synthesized according to procedures reported 
previously herein (Chapter II). All gels, buffers, and reagent/reagent kits were 
purchased from ThermoFisher. All compositional percentages are reported as v/v 
unless otherwise noted. Purified recombinant hRBBP9 was purchased from Novus 
Biologicals (Littleton, CO). Gels were electrophoresed on an XCell SureLock Mini-
Cell electrophoresis system (ThermoFisher) with a PowerPac power supply 
adapter from Bio-Rad. Fluorescent gels were scanned on a Typhoon 9200 flatbed 
imager (Amersham) and integrated using ImageJ software (NIH, Bethesda, MD). 
Analytical high-performance liquid chromatography (HPLC) was performed on an 
Agilent 1100 HPLC (Agilent, Santa Clara, CA) equipped with a reverse-phase 
Zorbax Eclipse XDB-C18 column (Agilent, 4.6 x 150 mm, 3.5 μm). The pH of 
phosphate-buffered saline (PBS) used in all experiments was 7.4 unless otherwise 
noted. 
IC50 Determination of VACV vs. RBBP9 by Gel-based ABPP 
Purified recombinant RBBP9 in PBS (5 μg∙mL-1) was pretreated with one of 
11 concentrations of VACV (0.01–3,000 μM) or vehicle for 2 min at RT, then 
labeled with AMB-FP-TAMRA (5 μM) at RT. After 5 min of labeling, aliquots were 
quenched in 1.25 volumes of SDS loading buffer and 0.25 volumes of 0.5 M 
dithiothreitol. Samples were heated to 90 °C for 10 min, and 15 μL per sample (30 
ng total protein) were electrophoresed on a 4–20% crosslinker gradient gel at 226 




TAMRA fluorescence and integrated on ImageJ software (National Institutes of 
Health, Bethesda, MD). The fluorescence intensities were normalized to the 
control (vehicle) and plotted against log [VACV]. The points were fitted to the two-
parameter Hill equation by nonlinear least-squares regression on Prism software 
(GraphPad, La Jolla, CA) with the IC50 and Hill slope thus estimated. 
Steady-State Michaelis-Menten Kinetic Assay 
 Purified recombinant hRBBP9 (0.5 μg∙mL-1) in PBS was incubated with 
eight concentrations of VACV (0.25–2 mM) at 37 °C in triplicate. Reactions were 
quenched after 2 min in four volumes MeOH with 0.1% TFA and pelleted for 5 min 
at 14,000 g. The supernatant was analyzed by HPLC using a binary solvent 
gradient from 2–90% acetonitrile/water (both with 0.1% TFA) at a 1.0 mL∙min-1 flow 
rate. Analytes were detected by absorbance at 254 nm. Relative peak areas were 
used to calculate hydrolytic activity. Non-enzymatic control reactions were used to 
account for chemical hydrolysis. Initial reaction velocities were fitted to the steady-
state Michaelis-Menten equation by nonlinear least-squares regression in Prism 
8.0 (GraphPad, La Jolla, CA). Protein concentrations were used as nominally 
labeled by the vendor in calculations of kcat. 
Half-Life Determination of Valyl-Gemcitabine in rRBBP9 
 Triplicate solutions of rRBBP9 (5 μg∙mL-1) in PBS or plain PBS were 
incubated with 5’-L-valyl-gemcitabine (1 mM) at 37 °C for 15 min, with aliquots 
quenched at 5, 10, and 15 min in four volumes MeOH with 0.1% TFA. After 
pelleting for 5 min at 14,000 g, the supernatant was analyzed by HPLC using a 




1.0 mL∙min-1 flow rate. Analytes were detected by absorbance at 254 nm. Relative 
peak areas were used to calculate half-life by fitting the quantity of prodrug 
remaining to a first-order exponential decay equation. 
Animals 
 Animal studies were conducted in accordance with the Guide for the Care 
and Use of Laboratory Animals as adopted and promulgated by the U.S. National 
Institutes of Health. Bphl-KO mice (pure C57BL/6 strain) were a generous gift from 
the Institut Clinique de la Souris (Illkirch Cedex, France) and were validated by 
genotyping. Gender-matched mice (pure C57BL/6 strain), 8–10 weeks old, were 
used in all the following procedures. The mice were kept in temperature-controlled 
housing with a 12/12-h light/dark cycle and received a standard diet and water ad 
libitum as provided by the Unit for Laboratory Animal Medicine, University of 
Michigan, Ann Arbor, MI. 
Lysate Preparation 
 One WT and one KO mouse, both male, were sacrificed by cervical 
dislocation and immediately dissected. The liver and jejunal segment were excised 
and rinsed in ice-cold PBS to remove blood and bowel remnants. Both tissues 
were cut into smaller pieces by razor and Dounce homogenized on ice. Crude 
lysates were spun 20 min at 9,000 x g and 4 °C, and the supernatant S9 fractions 
were centrifuged for another 60 min at 100,000 x g and 4 °C. The supernatant was 
used as the soluble fraction (S100), and the pellet was resuspended in PBS with 




aliquoted and stored at –80 °C until use. Animal dissection and organ harvesting 
were performed by Dr. Yongjun Hu. 
VACV Hydrolysis Assay with Emetine in Mouse Tissue Lysates 
 Triplicate mouse tissue lysate S100 fractions (1 mg∙mL-1) in PBS were 
incubated with emetine (1 mM) for 5 min at 37 °C. Reactions were initiated by the 
addition of VACV (1 mM) and were quenched 10 min after initiation in four volumes 
of MeOH with 0.1% TFA. Proteins were pelleted for 5 min at 14,000 g, followed by 
analysis of the supernatant via HPLC. A binary solvent gradient from 2% to 90% 
acetonitrile in water (both with 0.1% TFA) with 1.0 mL∙min-1 flow rate was used for 
separation. Analytes were detected by absorbance at 254 nm. External standards 
of VACV and ACV were used to calculate hydrolytic activity. Non-enzymatic control 
reactions were used to account for chemical hydrolysis. 
Single-Pass Intestinal Perfusions with and without Emetine 
 Mice were sedated and anesthetized by pentobarbital sodium injection prior 
to incision of the peritoneal cavity and cannulation of the small intestine. The 
perfusion solution contained 1 mM VACV ± 1 mM emetine in a pH 6.0 buffer 
containing 145 mM NaCl, 0.5 mM MgCl2, 1 mM NaH2PO4, 1 mM CaCl2, 3 mM KCl, 
5 mM glucose, and 5 mM MES. The pre-perfusion solutions with and without 
emetine were composed identically except without VACV. Emetine (or vehicle) 
pre-perfusion solution was perfused through the cannulated intestinal segment for 
60 min at 0.1 mL∙min-1 in a 31 °C perfusion chamber, followed by a 5 min perfusion 




~200 µL of portal blood was collected into a tube containing EDTA. This blood was 
centrifuged at 3,000 g for 4 min at 4 °C and a 50 µL sample of plasma collected.  
To the 50 µL plasma sample was then added 200 µL of ice-cold ACN 
containing 5 µM caffeine as an internal standard. The sample was then vortexed 
by hand and placed in the -20 °C freezer until all samples were collected. At this 
point, the sample was vortexed at 1500 rpm for 5 min and then centrifuged at 
17,000 g for 10 min at 4 °C. 200 µL of supernatant was transferred to a new tube 
and dried in a SpeedVac concentrator with heating at 45 °C for 1 h. The dried 
sample was then reconstituted in 80 µL water with 0.1% TFA, vortexed for 5 min 
at 1500 rpm, and bath sonicated for 5 min. The resulting solution was then 
centrifuged at 17,000 g for 10 min at 4 °C, of which 15 µL supernatant was 
analyzed by UPLC.  
The analytes were separated at 40 °C on an Acquity HSS T3 column (2.1 x 
100 mm), fitted with an HSS T3 VanGuard precolumn (2.1 x 5 mm).  The mobile 
phase flow rate was 0.5 mL∙min-1 and the same gradient was used as on 7/9/2019 
(100% water at 0 min, 90% water + 10% ACN at 5 min, 90% water + 10% ACN  at 
5.25 min, 30% water + 70% ACN at 7 min, 100% water at 8 min). The detection 
wavelengths for caffeine, VACV, and ACV were 275, 254, and 284 nm, 
respectively. The percentages of activated drug (
[𝐴𝐶𝑉]
[𝐴𝐶𝑉]+[𝑉𝐴𝐶𝑉]




) were calculated. Sample collection, data acquisition, and data 
analysis were performed by Brian Thompson. Experimental design and sample 






1.  Huttunen KM, Raunio H, Rautio J. Prodrugs--from Serendipity to Rational 
Design. Pharmacol Rev. 2011;63(3):750-771. doi:10.1124/pr.110.003459 
2.  Dammann HG, Burkhardt F, Wolf N. Enteric coating of aspirin significantly 
decreases gastroduodenal mucosal lesions. Aliment Pharmacol Ther. 
1999;13(8):1109-1114. doi:10.1046/j.1365-2036.1999.00588.x 
3.  Gupta S, Kesarla R, Omri A. Formulation strategies to improve the 
bioavailability of poorly absorbed drugs with special emphasis on self-
emulsifying systems. ISRN Pharm. 2013;2013:1-16. 
doi:10.1155/2013/848043 
4.  Sohi H, Sultana Y, Khar RK. Taste masking technologies in oral 
pharmaceuticals: recent developments and approaches. Drug Dev Ind 
Pharm. 2004;30(5):429-448. doi:10.1081/DDC-120037477 
5.  Ratnaparkhi P, Jyoti GP, Mukesh. Sustained release oral drug delivery 
system - an overview. Int J Pharma Res Rev IJPRR. 2013;2(23):11-21. 
6.  Rautio J, Meanwell NA, Di L, Hageman MJ. The expanding role of 
prodrugs in contemporary drug design and development. Nat Rev Drug 
Discov. 2018;17(8):559-587. doi:10.1038/nrd.2018.46 
7.  FDA F and DA. Guidance for Industry: Applications Covered by Section 
505(b)(2). Guidance. 1999;505(October):1-12. 
http://www.fda.gov/cder/guidance/index.htm. Accessed August 18, 2019. 
8.  Clas S-D, Sanchez RI, Nofsinger R. Chemistry-enabled drug delivery 
(prodrugs): recent progress and challenges. Drug Discov Today. 
2014;19(1):79-87. doi:10.1016/j.drudis.2013.08.014 
9.  Ram PR, Priyanka P, Shreekrishna L, Saroj S. Prodrug as a novel 
approach of drug delivery - a review. J Drug Deliv Ther. 2015;5(3):5-9. 
10.  Wu KM. A new classification of prodrugs: Regulatory perspectives. 
Pharmaceuticals. 2009;2(3):77-81. doi:10.3390/ph2030077 
11.  Tirkkonen T, Laine K. Drug interactions with the potential to prevent 
prodrug activation as a common source of irrational prescribing in hospital 
inpatients. Clin Pharmacol Ther. 2004;76(6):639-647. 
doi:10.1016/j.clpt.2004.08.017 
12.  Zhang C, Xu Y, Zhong Q, et al. In vitro evaluation of the inhibitory potential 




One. 2014;9(4). doi:10.1371/journal.pone.0093819 
13.  Harper TW, Brassil PJ. Reaction phenotyping: Current industry efforts to 
identify enzymes responsible for metabolizing drug candidates. AAPS J. 
2008;10(1):200-207. doi:10.1208/s12248-008-9019-6 
14.  Di L. Reaction phenotyping to assess victim drug-drug interaction risks. 
Expert Opin Drug Discov. 2017;12(11):1105-1115. 
doi:10.1080/17460441.2017.1367280 
15.  Zhang Y, Fonslow BR, Shan B, Baek M-C, Yates JR. Protein Analysis by 
Shotgun/Bottom-up Proteomics. 2013. doi:10.1021/cr3003533 
16.  Saghatelian A, Cravatt BF. Assignment of protein function in the 
postgenomic era. Nat Chem Biol. 2005;1(3):129. 
doi:10.1038/nchembio0805-130 
17.  Cravatt BF, Wright AT, Kozarich JW. Activity-Based Protein Profiling: From 
Enzyme Chemistry to Proteomic Chemistry. Annu Rev Biochem. 
2008;77(1):383-414. doi:10.1146/annurev.biochem.75.101304.124125 
18.  Liu Y, Patricelli MP, Cravatt BF. Activity-based protein profiling: The serine 
hydrolases. Proc Natl Acad Sci. 1999;96(26):14694-14699. 
doi:10.1073/pnas.96.26.14694 
19.  van Rooden EJ, Bakker AT, Overkleeft HS, van der Stelt M. Activity-Based 
Protein Profiling. eLS. 2018:1-9. doi:10.1002/9780470015902.a0023406 
20.  Wang K, Yang T, Wu Q, Zhao X, Nice EC, Huang C. Chemistry-based 
functional proteomics for drug target deconvolution. Expert Rev 
Proteomics. 2012;9(3):293-310. doi:10.1586/epr.12.19 
21.  Jeffery DA, Bogyo M. Chemical proteomics and its application to drug 
discovery. Curr Opin Biotechnol. 2003;14(1):87-95. doi:10.1016/S0958-
1669(02)00010-1 
22.  Bantscheff M, Scholten A, Heck AJR. Revealing promiscuous drug-target 
interactions by chemical proteomics. Drug Discov Today. 2009;14(21-
22):1021-1029. doi:10.1016/j.drudis.2009.07.001 
23.  Xu H, Majmudar JD, Davda D, et al. Substrate-Competitive Activity-Based 
Profiling of Ester Prodrug Activating Enzymes. Mol Pharm. 
2015;12(9):3399-3407. doi:10.1021/acs.molpharmaceut.5b00414 
24.  Liederer BM, Borchardt RT. Enzymes involved in the bioconversion of 
ester-based prodrugs. J Pharm Sci. 2006;95(6):1177-1195. 
doi:10.1002/jps.20542 
25.  Sun Z, Murry DJ, Sanghani SP, et al. Methylphenidate is stereoselectively 





26.  Pindel E V., Kedishvili LNY, Abraham TL, et al. Purification and cloning of a 
human liver carboxylesterase that catalyzes the hydrolysis of cocaine and 
heroin. FASEB J. 1997;11(9):14769-14775. 
27.  Imai T, Ohura K. The Role of Intestinal Carboxylesterase in the Oral 
Absorption of Prodrugs. Curr Drug Metab. 2011;11(9):793-805. 
doi:10.2174/138920010794328904 
28.  Laizure SC, Parker RB, Herring VL, Hu ZY. Identification of 
carboxylesterase-dependent dabigatran etexilate hydrolysis. Drug Metab 
Dispos. 2014;42(2):201-206. doi:10.1124/dmd.113.054353 
29.  Shi D, Yang J, Yang D, et al. Anti-Influenza Prodrug Oseltamivir Is 
Activated by Carboxylesterase Human Carboxylesterase 1, and the 
Activation Is Inhibited by Antiplatelet Agent Clopidogrel. J Pharmacol Exp 
Ther. 2006;319(3):1477-1484. doi:10.1124/jpet.107.120030 
30.  Danks MK, Morton CL, Krull EJ, et al. Comparison of activation of CPT-11 
by rabbit and human carboxylesterases for use in enzyme/prodrug therapy. 
Clin Cancer Res. 1999;5(4):917-924. 
31.  Kim I, Chu XY, Kim S, Provoda CJ, Lee KD, Amidon GL. Identification of a 
human valacyclovirase: Biphenyl hydrolase-like protein as valacyclovir 
hydrolase. J Biol Chem. 2003;278(28):25348-25356. 
doi:10.1074/jbc.M302055200 
32.  Beauchamp LM, Orr GF, De Miranda P, Burnette T, Krenitsky TA. Amino 
acid ester prodrugs of acyclovir. Antivir Chem Chemother. 1992;3(3):157-
164. doi:10.1177/095632029200300305 
33.  Ganapathy ME, Huang W, Wang H, Ganapathy V, Leibach FH. 
Valacyclovir: A substrate for the intestinal and renal peptide transporters 
PEPT1 and PEPT2. Biochem Biophys Res Commun. 1998;246(2):470-
475. doi:10.1006/bbrc.1998.8628 
34.  Balimane P V., Tamai I, Guo A, et al. Direct evidence for peptide 
transporter (PepT1)-mediated uptake of a nonpeptide prodrug, 
valacyclovir. Biochem Biophys Res Commun. 1998;250(2):246-251. 
doi:10.1006/bbrc.1998.9298 
35.  Lai L, Xu Z, Zhou J, Lee K-D, Amidon GL. Molecular Basis of Prodrug 
Activation by Human Valacyclovirase, an a-Amino Acid Ester Hydrolase. J 
Biol Chem. 2008;283(14):9318-9327. doi:10.1074/jbc.M709530200 
36.  Kim I, Song X, Vig BS, et al. A novel nucleoside prodrug-activating 
enzyme: substrate specificity of biphenyl hydrolase-like protein. Mol 
Pharm. 2004;1(2):117-127. doi:10.1021/mp0499757 
37.  Kim I, Crippen GM, Amidon GL. Structure and specificity of a human 





38.  Sun J, Dahan A, Walls ZF, Lai L, Lee KD, Amidon GL. Specificity of a 
prodrug-activating enzyme hVACVase: The leaving group effect. Mol 
Pharm. 2010;7(6):2362-2368. doi:10.1021/mp100300k 
39.  Sun J, Dahan A, Amidon GL. Enhancing the intestinal absorption of 
molecules containing the polar guanidino functionality: A double-targeted 
prodrug approach. J Med Chem. 2010;53(2):624-632. 
doi:10.1021/jm9011559 
40.  Dahan A, Khamis M, Agbaria R, Karaman R. Targeted prodrugs in oral 
drug delivery: the modern molecular biopharmaceutical approach. Expert 
Opin Drug Deliv. 2012;9(8):1001-1013. 
doi:10.1517/17425247.2012.697055 
41.  Kim I. A Novel Prodrug Activating Enzyme: Identification and 
Characterization of BPHL. Dr Thesis. 2004. doi:10.1016/B978-012397720-
5.50034-7 
42.  Hu Y, Epling D, Shi J, et al. Effect of biphenyl hydrolase-like (BPHL) gene 
disruption on the intestinal stability, permeability and absorption of 
valacyclovir in wildtype and Bphl knockout mice. Biochem Pharmacol. 
2018;156(August):147-156. doi:10.1016/j.bcp.2018.08.018 
43.  Patricelli MP, Giang DK, Stamp LM, Burbaum JJ. Direct visualization of 
serine hydrolase activities in complex proteomes using fluorescent active 
site-directed probes. Proteomics. 2001;1(9):1067-1071. doi:10.1002/1615-
9861(200109)1:9<1067::AID-PROT1067>3.0.CO;2-4 
44.  Bachovchin DA, Ji T, Li W, et al. Superfamily-wide portrait of serine 
hydrolase inhibition achieved by library-versus-library screening. Proc Natl 
Acad Sci U S A. 2010;107(49):20941-20946. 
doi:10.1073/pnas.1011663107 
45.  Lai L. Structure and Function of a Prodrug Activating Enzyme Valacyclovir 
Hydrolase. Dr Thesis. 2006. doi:10.1017/S0165115300023299 
46.  Middleton WJ. New Fluorinating Reagents. Dialkylaminosulfur Fluorides. J 
Org Chem. 1975;40(5):574-578. doi:10.1021/jo00893a007 
47.  Burger A, Anderson JJ. Monoesters and Ester-amidates of Aromatic 
Phosphonic Acids. J Am Chem Soc. 1957;79(13):3575-3579. 
doi:10.1021/ja01570a073 
48.  Xu H, Sabit H, Amidon GL, Showalter HDH. An improved synthesis of a 
fluorophosphonate-polyethylene glycol-biotin probe and its use against 
competitive substrates. Beilstein J Org Chem. 2013;9:89-96. 
doi:10.3762/bjoc.9.12 
49.  McKenna CE, Higa MT, Cheung NH, McKenna MC. The facile dealkylation 
of phosphonic acid dialkyl esters by bromotrimethylsilane. Tetrahedron 




50.  Kidd D, Liu Y, Cravatt BF. Profiling serine hydrolase activities in complex 
proteomes. Biochemistry. 2001;40(13):4005-4015. doi:10.1021/bi002579j 
51.  Strelow JM. A Perspective on the Kinetics of Covalent and Irreversible 
Inhibition. J Biomol Screen. 2017;22(1):3-20. 
doi:10.1177/1087057116671509 
52.  Worek F, Thiermann H, Szinicz L, Eyer P. Kinetic analysis of interactions 
between human acetylcholinesterase, structurally different 
organophosphorus compounds and oximes. Biochem Pharmacol. 
2004;68(11):2237-2248. doi:10.1016/j.bcp.2004.07.038 
53.  Adibekian A, Martin BR, Chang JW, et al. Confirming target engagement 
for reversible inhibitors in vivo by kinetically tuned activity-based probes. J 
Am Chem Soc. 2012;134(25):10345-10348. doi:10.1021/ja303400u 
54.  Sharman J, Pennick M. Lisdexamfetamine prodrug activation by peptidase-
mediated hydrolysis in the cytosol of red blood cells. Neuropsychiatr Dis 
Treat. 2014;10:2275-2280. doi:10.2147/NDT.S70382 
55.  Speers AE, Cravatt BF. Profiling enzyme activities in vivo using click 
chemistry methods. Chem Biol. 2004;11(4):535-546. 
doi:10.1016/j.chembiol.2004.03.012 
56.  Harsha HC, Molina H, Pandey A. Quantitative proteomics using stable 
isotope labeling with amino acids in cell culture. Nat Protoc. 2008;3(3):505-
516. doi:10.1038/nprot.2008.2 
57.  Yang Y, Yang X, Verhelst SHL. Comparative analysis of click chemistry 
mediated activity-based protein profiling in cell lysates. Molecules. 
2013;18(10):12599-12608. doi:10.3390/molecules181012599 
58.  Bachovchin DA, Brown SJ, Rosen H, Cravatt BF. Identification of selective 
inhibitors of uncharacterized enzymes by high-throughput screening with 
fluorescent activity-based probes. Nat Biotechnol. 2009;27(4):387-394. 
doi:10.1038/nbt.1531 
59.  Bachovchin DA, Koblan LW, Wu W, et al. A high-throughput, multiplexed 
assay for superfamily-wide profiling of enzyme activity. Nat Chem Biol. 
2014;10(8):656-663. doi:10.1038/nchembio.1578 
60.  Bachovchin DA, Mohr JT, Speers AE, et al. Academic cross-fertilization by 
public screening yields a remarkable class of protein phosphatase 
methylesterase-1 inhibitors. Proc Natl Acad Sci U S A. 2011;108(17):6811-
6816. doi:10.1073/pnas.1015248108 
61.  Wilk S, Orlowski M. Inhibition of Rabbit Brain Prolyl Endopeptidase by N‐
Benzyloxycarbonyl‐Prolyl‐Prolinal, a Transition State Aldehyde Inhibitor. J 
Neurochem. 1983;41(1):69-75. doi:10.1111/j.1471-4159.1983.tb11815.x 




Tyrosine Residues Using Sulfonyl Fluoride Probes. 2015. 
doi:10.1021/cb5009475 
63.  M. Vorobiev S, Janet Huang Y, Seetharaman J, et al. Human 
Retinoblastoma Binding Protein 9, a Serine Hydrolase Implicated in 
Pancreatic Cancers. Protein Pept Lett. 2012;19(2):194-197. 
doi:10.2174/092986612799080356 
64.  Woitach JT, Zhang M, Niu CH, Thorgeirsson SS. A retinoblastoma-binding 
protein that affects cell-cycle control and confers transforming ability. Nat 
Genet. 1998;19(4):371-374. doi:10.1038/1258 
65.  Shields DJ, Niessen S, Murphy EA, et al. RBBP9: A tumor-associated 
serine hydrolase activity required for pancreatic neoplasia. Proc Natl Acad 
Sci. 2010;107(5):2189-2194. doi:10.1073/pnas.0911646107 
66.  Vorobiev SM, Su M, Seetharaman J, et al. Crystal structure of human 
retinoblastoma binding protein 9. Proteins Struct Funct Bioinforma. 
2009;74(2):526-529. doi:10.1002/prot.22278 
67.  Simon GM, Cravatt BF. Activity-based proteomics of enzyme 
superfamilies: Serine hydrolases as a case study. J Biol Chem. 
2010;285(15):11051-11055. doi:10.1074/jbc.R109.097600 
68.  Hidalgo IJ, Li J. Carrier-mediated transport and efflux mechanisms of 
Caco-2 cells. Adv Drug Deliv Rev. 1996;22(1-2):53-66. doi:10.1016/S0169-
409X(96)00414-0 
69.  Sambuy Y, De Angelis I, Ranaldi G, Scarino ML, Stammati A, Zucco F. 
The Caco-2 cell line as a model of the intestinal barrier: influence of cell 
and culture-related factors on Caco-2 cell functional characteristics. Cell 
Biol Toxicol. 2005;21(1):1-26. doi:10.1007/s10565-005-0085-6 
70.  Imai, Teruko; Masumi, Imoto; Sakamoto, Hisae; Hashimoto M. 
Identification of esterases expressed in Caco-2 cells and effects of their 
hydrolyzing activity in predicting human intestinal absorption. Drug Metab 
Dispos. 2005;33(8):1185-1190. doi:10.1124/dmd.105.004226.tion 
71.  Imai T, Taketani M, Shii M, Hosokawa M, Chiba K. Substrate specificity of 
carboxylesterase isozymes and their contribution to hydrolase activity in 
human liver and small intestine. Drug Metab Dispos. 2006;34(10):1734-
1741. doi:10.1124/dmd.106.009381 
72.  Hosokawa M. Structure and catalytic properties of carboxylesterase 
isozymes involved in metabolic activation of prodrugs. Molecules. 
2008;13(2):412-431. doi:10.3390/molecules13020412 
73.  Bar-Even A, Noor E, Savir Y, et al. The moderately efficient enzyme: 
Evolutionary and physicochemical trends shaping enzyme parameters. 
Biochemistry. 2011;50(21):4402-4410. doi:10.1021/bi2002289 




absorption and pharmacokinetics of valacyclovir after oral dose escalation 
in wild-type and PepT1 knockout mice. Drug Metab Dispos. 
2013;41(10):1867-1874. doi:10.1124/dmd.113.052597 
75.  Hidalgo IJ, Raub TJ, Borchardt RT. Characterization of the Human Colon 
Carcinoma Cell Line (Caco-2) as a Model System for Intestinal Epithelial 
Permeability. Gastroenterology. 1989;96(2):736-749. doi:10.1016/S0016-
5085(89)80072-1 
76.  Inoue M, Morikawa M, Tsuboi M, Sugiura M. Species Difference and 
Characterization of Intestinal Esterase on the Hydrolizing Activity of Ester-
Type Drugs. Jpn J Pharmacol. 1979;29(1):9-16. doi:10.1254/jjp.29.9 
77.  Taketani M, Shii M, Ohura K, Ninomiya S, Imai T. Carboxylesterase in the 
liver and small intestine of experimental animals and human. Life Sci. 
2007;81(11):924-932. doi:10.1016/j.lfs.2007.07.026 
78.  Puente XS, Lopez-Otin C. Cloning and Expression Analysis of a Novel 
Human Serine Hydrolase with Sequence Similarity to Prokaryotic Enzymes 
Involved in the Degradation of Aromatic Compounds. J Biol Chem. 
1995;270(21):12926-12932. doi:10.1074/jbc.270.21.12926 
79.  Debbage PL, Griebel J, Ried M, Gneiting T, DeVries A, Hutzler P. Lectin 
intravital perfusion studies in tumor-bearing mice: Micrometer- resolution, 
wide-area mapping of microvascular labeling, distinguishing efficiently and 









 Prodrugs, latent drug derivatives activated within the body, are an essential 
tool for overcoming issues with the parent drug that cannot be resolved by 
formulation or analog generation. The best prodrug solution available will vary 
significantly depending on case-specific circumstances, but one piece of 
information is invariably crucial: the prodrug-activating enzyme (PAE) profile. 
Because a prodrug will not take proper effect until activation, knowing when, 
where, and how it is activated is central to studying its safety, tolerability, and 
efficacy. The first step, then, in the study of prodrug candidates should be the 
identification of PAEs so that one can subsequently study preclinical species 
orthologs for animal model selection, human pharmacogenetic variants for 
prediction of interindividual variability, and drug interactions with other drugs, 
foods, or disease states. An additional benefit is the possibility of targeted prodrugs 
against a given PAE by empirical or structure-based prodrug design, which could 
enable tissue- or cell-selective activation of toxic drugs used in chemotherapy or 
as antibiotics/antivirals. The prodrug strategy is typically used as a late-stage 
intervention to salvage failing drug candidates instead of taking a large financial 
loss on the investment, but identification of PAEs and subsequently characterizing 
them can substantially de-risk early-stage implementation of the prodrug strategy, 




 In spite of the need for PAE identification, many prodrugs are developed 
without this knowledge, with many instances of PAEs not being identified until 
several years after prodrug approval. The typical approach to PAE identification 
uses activity-guided fractionation, which is tedious and time-consuming. Our lab 
adapted a relatively recent chemical biology technique, known as activity-based 
protein profiling (ABPP), for faster identification of serine hydrolase (SH) PAEs by 
modifying the standard fluorophosphonate (FP) activity-based probe (ABP). The 
prodrug we focused on, valacyclovir (VACV), was approved in 1995, but the PAE 
biphenyl hydrolase-like protein (BPHL) was not discovered until 2003 in our lab by 
activity-guided fractionation from Caco-2 cells. This SH was shown by various 
experiments to not be obligatory for the conversion of VACV to acyclovir (ACV) in 
vivo. The commercially available standard FP ABP did not inhibit VACV activation 
in Caco-2 lysates, so we set out to modify the probe. 
 In Chapter 2, we describe the semi-rational design of this novel probe based 
on the observation that pan-serine protease inhibitor 4-(2-
aminoethyl)benzylsulfonyl fluoride (AEBSF) abolished VACV activation in Caco-2 
lysates. While direct esterification of the phenolic analog of AEBSF, tyramine, to 
the phosphonate group in the commercial FP ABP was not fruitful, the isobaric 
benzylic isomer, 4-(aminomethyl)benzyl alcohol (AMB), was successfully installed 
using dicyclohexylcarbodiimide in refluxing tetrahydrofuran, yielding novel AMB-
FP probes. Both the alkyne and TAMRA versions of the probe were thus 
synthesized, whereas the biotinylated probe was unstable in storage. These novel 




2 lysate, but none of them inhibited recombinant human BPHL, suggesting that 
they were targeting undiscovered VACV PAEs. VACV activation was inhibited in 
Bphl knockout mice jejunum and liver lysates as well, corroborating this finding. 
After optimization of probe labeling conditions, in-gel visualization revealed that 
AMB-FP and FP probes were broad-spectrum probes, but that FP reacted with 
more targets and labeled them faster. Both probes labeled some targets to a 
greater extent than the other, and a few targets were exclusively labeled by one 
probe. 
 In Chapter 3, a competitive ABPP (cABPP) assay with VACV was 
developed and optimized in-gel to determine the proper time at which competition 
is best observed. Irreversible inhibitors such as probes reduce the free enzyme 
population, eventually labeling all available enzyme if present in excess and 
reducing to zero the signal difference between samples with and without prodrug 
present. Gel-based cABPP confirmed that the VACV PAEs were only present in 
the soluble fraction (S100) and not the membrane fraction. Once the ideal 
timepoint was selected, the cABPP assay was adapted to an MS-compatible 
format and Caco-2 cells were grown in SILAC media to label all proteins with 
heavier Arg and Lys isotopologs. In the assay, three SHs were identified as targets 
of VACV: PPME1, PPCE, and RBBP9. Fortunately, well-characterized selective 
inhibitors were commercially available for all candidate PAEs. Co-incubation of 
each inhibitor with VACV in Caco-2 S100 led to the confirmation of only RBBP9 as 




based cABPP assay and against rBPHL, confirming that no off-target interactions 
were confounding the results. 
 In Chapter 4, the activity of RBBP9 was characterized in vitro and in situ 
and compared to the data reported for BPHL. Recombinant human RBBP9 was 
purchased and the IC50 of VACV was assayed to show single-binding 
stoichiometry via fitting of the Hill equation. This justified the kinetic 
characterization of RBBP9 VACV activation via the Michaelis-Menten model, 
which demonstrated that the catalytic efficiency of RBBP9 was about half that of 
BPHL, with tenfold lower affinity for VACV but a roughly fivefold greater turnover 
rate. Then emetine inhibition was assayed in WT and Bphl-KO mouse jejunum and 
liver lysates, where the data indicated that RBBP9 and BPHL are essentially the 
only VACV PAEs in those tissues. In the liver, BPHL and RBBP9 both comprised 
about half of the total activity each. In the jejunum, which had under 40% of the 
total liver activity, three-fourths of the activity was attributable to RBBP9. In the 
knockout tissues, virtually all the activity was due to RBBP9. Subsequently, single-
pass intestinal perfusions were carried out in mice with and without emetine pre-
perfusion and demonstrated significant reduction in portal vein activation of VACV, 
resulting in >50% increase in unactivated prodrug levels.  
Taken together, all the preceding results imply with high likelihood that 
RBBP9 is involved in the in vivo disposition of oral valacyclovir as a presystemic 
PAE and plays a pre-eminent role in the gut and a major role in the liver. These 
two enzymes, in wildtype individuals, are likely to be the only two presystemic 




further experiments. Incidentally, VACV represents the first reported substrate of 
RBBP9 and hopefully can serve as a starting point to discover more substrates, 
especially endogenous ones. Future directions with respect to this enzyme include 
the aforementioned studies: characterization of interspecies differences, 
pharmacogenomic variability, drug interactions, and substrate-activity 
relationships. Beyond this enzyme, the broader application of cABPP as a tool for 
PAE identification might be very useful, particularly in cases where rudimentary 
reaction phenotyping methods cannot identify individual PAEs. This concept 
extends beyond the SH family and could be useful for PAEs belonging to other 
hydrolase families and many other mechanistic enzyme subclasses with well-
developed suites of ABPs. We hope that the ensuing discoveries, by broadening 
and deepening the understanding of molecular physiology and de-risking early-
stage prodrug ventures, greatly benefit prodrug discovery and development efforts 
in academia and the pharmaceutical industry. 
 
 
